TREATMENT READING
Childhood Soft Tissue Sarcoma
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
242 sections
- Treatment Option Overview for Childhood Soft Tissue Sarcoma
- Surgery
- Radiation Therapy
- Preoperative radiation therapy
- Postoperative radiation therapy
- Dose and volume
- Chemotherapy
- Targeted Therapy
- Special Considerations for the Treatment of Children With Soft Tissue Sarcoma
- Treatment of Adipocytic Tumors
- Liposarcoma, Well-Differentiated, Not Otherwise Specified (NOS)
- Clinical presentation
- Histopathological classification
- Genomic alterations
- Prognosis
- Treatment of liposarcoma
- Surgery
- Chemotherapy
- Surgery and radiation therapy
- Targeted therapy
- Treatment of Chondro-osseous Tumors
- Extraskeletal Mesenchymal Chondrosarcoma
- Histopathological features and genomic alterations
- Prognostic factors and prognosis
- Treatment of extraskeletal mesenchymal chondrosarcoma
- Osteosarcoma, Extraskeletal
- Genomic alterations
- Prognostic factors and prognosis
- Treatment of extraskeletal osteosarcoma
- Treatment of Fibroblastic and Myofibroblastic Tumors
- Desmoid-Type Fibromatosis
- Genomic alterations
- Treatment of desmoid-type fibromatosis
- Observation
- Chemotherapy, for unresectable or recurrent tumors
- Tyrosine kinase inhibitors
- NOTCH pathway/gamma-secretase inhibitors
- NSAIDs
- Antiestrogen treatment
- Surgery
- Radiation therapy
- Treatment options under clinical evaluation
- Dermatofibrosarcoma Protuberans NOS
- Genomic alterations
- Treatment of dermatofibrosarcoma protuberans
- Surgery with or without radiation therapy
- Targeted therapy (imatinib)
- Inflammatory Myofibroblastic Tumor and Epithelioid Inflammatory Myofibroblastic Sarcoma
- Clinical presentation
- Genomic alterations
- Prognosis
- Treatment of inflammatory myofibroblastic tumor
- Surgery and chemotherapy
- Steroid therapy or NSAID therapy
- Targeted therapy (ALK inhibitors)
- Infantile Fibrosarcoma
- Clinical presentation
- Genomic alterations
- Treatment of infantile fibrosarcoma
- Surgery, observation, and/or chemotherapy
- Targeted therapy
- Treatment options under clinical evaluation
- Fibrosarcoma NOS
- Myxofibrosarcoma
- Low-Grade Fibromyxoid Sarcoma
- Genomic alterations
- Prognosis
- Treatment of low-grade fibromyxoid sarcoma
- Sclerosing Epithelioid Fibrosarcoma
- Genomic characteristics
- Treatment of sclerosing epithelioid fibrosarcoma
- Treatment of Skeletal Muscle Tumors
- Rhabdomyosarcoma
- Ectomesenchymoma
- Histological features and genomic alterations
- Treatment of ectomesenchymoma
- Treatment of Smooth Muscle Tumors
- Leiomyosarcoma Not Otherwise Specified (NOS)
- Risk factors
- Treatment of leiomyosarcoma
- Treatment of So-Called Fibrohistiocytic Tumors
- Plexiform Fibrohistiocytic Tumor
- Clinical presentation
- Genomic alterations
- Treatment of plexiform fibrohistiocytic tumor
- Treatment of Peripheral Nerve Sheath Tumors
- Malignant Peripheral Nerve Sheath Tumor (MPNST) NOS
- Risk factors
- Histological features, diagnostic evaluation, and genomic alterations
- Prognostic factors and prognosis
- Treatment of MPNST
- Surgery preceded or followed by radiation therapy
- Chemotherapy
- Recurrent MPNST
- Treatment options under clinical evaluation
- Malignant Triton Tumor
- Treatment of Pericytic (Perivascular) Tumors
- Myopericytoma
- Histology
- Treatment and outcome of infantile hemangiopericytomas
- Infantile Myofibromatosis
- Genomic alterations and genetic testing
- Treatment and outcome of infantile myofibromatosis
- Treatment of Tumors of Uncertain Differentiation
- Myxoma NOS
- Carney complex
- Synovial Sarcoma NOS (Poorly Differentiated, Spindle Cell, and Biphasic Varieties)
- Clinical presentation
- Histological features, diagnostic evaluation, and genomic alterations
- Prognostic factors
- Treatment of synovial sarcoma
- Surgery alone
- Surgery and chemotherapy, with or without radiation therapy
- Recurrent synovial sarcoma NOS
- Treatment options under clinical evaluation
- Epithelioid Sarcoma
- Clinical presentation
- Genomic alterations
- Treatment of epithelioid sarcoma
- Surgery with or without chemotherapy and/or radiation therapy
- Targeted therapy
- Treatment options under clinical evaluation for epithelioid sarcoma
- Alveolar Soft Part Sarcoma
- Clinical presentation
- Genomic alterations
- Prognosis
- Treatment of alveolar soft part sarcoma
- Surgery with or without radiation therapy and chemotherapy
- Targeted therapy
- Other therapies
- Treatment options under clinical evaluation for alveolar soft part sarcoma
- Clear Cell Sarcoma NOS
- Clinical presentation
- Genomic alterations
- Treatment of clear cell sarcoma of soft tissue
- Surgery with or without radiation therapy
- Targeted therapy
- Extraskeletal Myxoid Chondrosarcoma
- Genomic alterations
- Treatment of extraskeletal myxoid chondrosarcoma
- Extraskeletal Ewing Sarcoma
- Desmoplastic Small Round Cell Tumor
- Clinical presentation
- Diagnostic evaluation
- Genomic alterations
- Prognosis
- Treatment of desmoplastic small round cell tumor
- Multimodality therapy
- Surgery with HIPEC
- Other treatment options
- Rhabdoid Tumor NOS (Extrarenal)
- Genetic and genomic alterations
- Genetic testing and surveillance
- Prognosis and clinical presentation
- Treatment of extrarenal (extracranial) rhabdoid tumor
- Treatment options under clinical evaluation
- PEComa, Malignant
- Clinical presentation
- Risk factors and molecular features
- Prognosis
- Treatment of PEComas
- Undifferentiated Sarcoma
- Pleomorphic Sarcoma, Undifferentiated (Malignant Fibrous Histiocytoma)
- Clinical presentation
- Risk factors
- Molecular features
- Treatment of newly diagnosed pleomorphic sarcoma
- Treatment of recurrent or refractory pleomorphic sarcoma
- Intracranial Mesenchymal Tumor
- Round Cell Sarcoma, Undifferentiated
- Undifferentiated small round cell sarcomas with BCOR genetic alterations
- Undifferentiated small round cell sarcomas with CIC genetic alterations
- Undifferentiated small round cell sarcomas with EWSR1::non-ETS fusions
- Treatment of Vascular Tumors
- Epithelioid Hemangioendothelioma NOS
- Incidence and outcome
- Clinical presentation and diagnostic evaluation
- Genomic alterations and histopathological features
- Treatment of epithelioid hemangioendothelioma
- Treatment options under clinical evaluation for epithelioid hemangioendothelioma
- Angiosarcoma
- Incidence and clinical presentation
- Risk factors
- Genomic alterations and histopathological features
- Treatment of angiosarcoma
- Surgery
- Radiation therapy
- Surgery, chemotherapy, and radiation therapy
- Palliative care
- Treatment options under clinical evaluation for angiosarcoma
- Treatment of Metastatic Childhood Soft Tissue Sarcoma
- Pulmonary Metastases
- Treatment of Progressive or Recurrent Childhood Soft Tissue Sarcoma
- Surgery
- Chemotherapy
- Tyrosine Kinase Inhibitors
- Immune Checkpoint Inhibitors
- Treatment Options Under Clinical Evaluation
- Types of treatment for childhood soft tissue sarcoma
- Who treats children with soft tissue sarcoma?
- Surgery
- Radiation therapy
- Chemotherapy
- Observation
- Targeted therapy
- Immunotherapy
- Clinical trials
- Treatment of childhood soft tissue sarcoma
- Blood vessel tumors
- Epithelioid hemangioendothelioma
- Angiosarcoma
- Bone tumors
- Extraskeletal osteosarcoma
- Cartilage tumors
- Extraskeletal mesenchymal chondrosarcoma
- Fat tissue tumors
- Liposarcoma
- Fibrous connective tissue tumors
- Dermatofibrosarcoma protuberans
- Fibrosarcoma
- Infantile fibrosarcoma
- Adult-type fibrosarcoma
- Myxofibrosarcoma
- Low-grade fibromyxoid sarcoma
- Pericytic (perivascular) tumors
- Infantile hemangiopericytoma
- Skeletal muscle tumors
- Rhabdomyosarcoma
- Ectomesenchymoma
- So-called fibrohistiocytic tumors
- Plexiform fibrohistiocytic tumor
- Tumors of unknown cell origin (the place where the tumor first formed is not known)
- Myxoma (Carney complex)
- Epithelioid sarcoma
- Extraskeletal myxoid chondrosarcoma
- Extraskeletal Ewing sarcoma
- Perivascular epithelioid cell tumors (PEComas)
- Undifferentiated or unclassified sarcoma
- Undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma)
- Metastatic childhood soft tissue sarcoma
- Treatment of progressive or recurrent childhood soft tissue sarcoma
- Side effects and late effects of treatment
Treatment Option Overview for Childhood Soft Tissue Sarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Because of the rarity of pediatric nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS), treatment should be coordinated by a multidisciplinary team that includes oncologists (pediatric or medical), pathologists, surgeons, and radiation oncologists for all children, adolescents, and young adults with these tumors. In addition, to better define the tumors' natural history and response to therapy, entry into national or institutional treatment protocols should be considered for children with rare neoplasms. Information about ongoing clinical trials is available from the NCI website.
Sources: NCI website
The Children's Oncology Group (COG) performed a prospective nonrandomized trial (ARST0332 [NCT00346164]) for patients with soft tissue sarcomas.[1]
Sources: ARST0332 [NCT00346164] · 1
Surgical resection of the primary tumor was classified as follows:
R0 if the resection was complete with negative microscopic margins.
R1 if the margins were microscopically positive.
R2 if the resection left macroscopic residual tumor.
Patients were assigned to one of the following three risk groups:
Low risk: Nonmetastatic R0 or R1 low-grade, or ≤5 cm R1 high-grade tumor.
Intermediate risk: Nonmetastatic R0 or R1 >5 cm high-grade, or unresected tumor of any size or grade.
High risk: Metastatic tumor.
The treatment groups were as follows:
Surgery alone.
Radiation therapy (55.8 Gy).
Chemoradiation therapy (chemotherapy and 55.8 Gy radiation therapy).
Neoadjuvant chemoradiation therapy (chemotherapy and 45 Gy radiation therapy, then surgery and radiation therapy boost based on margins with continued chemotherapy).
Chemotherapy included six cycles of intravenous (IV) ifosfamide (3 g/m2 per dose) on days 1 through 3 and five cycles of IV doxorubicin (37.5 mg/m2 per dose) on days 1 to 2 every 3 weeks, with the sequence adjusted based on timing of surgery or radiation therapy.
The analysis included 529 evaluable patients: low risk (n = 222), intermediate risk (n = 227), and high risk (n = 80). Patients underwent surgery alone (n = 205), radiation therapy (n = 17), chemoradiation therapy (n = 111), and neoadjuvant chemoradiation therapy (n = 196).
At a median follow-up of 6.5 years (interquartile range [IQR], 4.9–7.9), the 5-year event-free survival (EFS) and overall survival (OS) rates, by risk group, were as follows:
Low-risk group: EFS rate, 88.9% (95% confidence interval [CI], 84.0%–93.8%) and OS rate, 96.2% (95% CI, 93.2%–99.2%).
Intermediate-risk group: EFS rate, 65.0% (95% CI, 58.2%–71.8%) and OS rate, 79.2% (95% CI, 73.4%–85.0%).
High-risk group: EFS rate, 21.2% (95% CI, 11.4%–31.1%) and OS rate, 35.5% (95% CI, 23.6%–47.4%).
The authors concluded that pretreatment clinical features can be used to effectively define treatment failure risk and stratify young patients with NRSTS for risk-adapted therapy. Most low-risk patients can be cured without adjuvant therapy, avoiding known long-term treatment complications. Survival remains suboptimal for intermediate-risk and high-risk patients, and novel therapies are needed for these patients.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Surgery
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Surgical resection of the primary tumor is the predominant therapy for most NRSTS. In the COG ARST0332 (NCT00346164) study, approximately 37% of patients younger than 30 years were treated with surgery alone.[1] Another 36% of patients had surgical resection after neoadjuvant chemoradiation therapy. Involvement of a surgeon with special expertise in the resection of soft tissue sarcomas is highly desirable.
Sources: ARST0332 (NCT00346164) · 1
After an appropriate biopsy and pathological diagnosis, every attempt is made to resect the primary tumor. Completeness of resection predicts outcome. In the COG ARST0332 study, complete resections with negative microscopic margins (R0) resulted in the best outcomes.[1]
Sources: 1
The 5-year EFS rates for patients treated with surgery and other modalities were the following:
The 5-year EFS rates for patients treated with surgery and other modalities were the following:
84% for patients who had R0 resections.
66% for patients who had R1 resections.
49% for patients who had R2 resections.
The 5-year OS rates for patients treated with surgery and other modalities were the following:
The 5-year OS rates for patients treated with surgery and other modalities were the following:
93% for patients who had R0 resections.
80% for patients who had R1 resections.
63% for patients who had R2 resections.
The 5-year EFS rates for patients treated with surgery only were the following:
The 5-year EFS rates for patients treated with surgery only were the following:
96% for patients with low-grade tumors who had R0 resections.
81% for patients with low-grade tumors who had R1 resections.
84% for patients with high-grade tumors that were smaller than 5 cm and had R0 resections.
The COG reported results for the subset of patients with low-grade NRSTS enrolled in the ARST0332 study.[2] Low-risk patients were treated with surgery alone. Intermediate- and high-risk patients received ifosfamide/doxorubicin and radiation therapy, with definitive resection either before or after 12 weeks of chemotherapy and radiation therapy.
Sources: 2
| Risk Group | 5-Year Event-Free Survival Rate | 5-Year Overall Survival Rate |
|---|---|---|
| Low risk | 90% | 100% |
| Intermediate risk | 55% | 78% |
| High risk | 25% | 25% |
In low-risk patients, local-only recurrences were seen in 10% of patients. No patients with margins of resection greater than 1 mm had local recurrences.
Sixteen of 17 intermediate- and high-risk patients who completed neoadjuvant chemotherapy and radiation therapy underwent gross-total tumor resection, and 80% had negative margins.
In the intermediate- and high-risk groups, events included one local recurrence and seven metastatic recurrences.
The timing of surgery depends on an assessment of the feasibility and morbidity of surgery. In the COG ARST0332 study, if the central review surgeon deemed the tumor unresectable without loss of limb, form, or function, the patient was treated in arm C with neoadjuvant radiation therapy. Surgery was performed 4 to 6 weeks after the completion of radiation therapy. This early surgery allowed for decreased morbidity, better wound healing, and more complete surgical resection. The outcomes in the COG ARST0332 study were nearly identical for intermediate-risk patients who achieved an R0 or R1 resection with up-front surgery or surgery after neoadjuvant chemoradiation therapy (70% vs. 71%, respectively). An R0 resection was more likely to occur after neoadjuvant therapy.[1] These observations are true even for high-grade tumors, where the ability to achieve R0 or R1 resections was the major predictor of EFS. Treatment with neoadjuvant chemoradiation therapy resulted in lower doses of radiation therapy and achieved greater rates of R0 resections.[3] Resectability should be determined at the time of diagnosis. While there should be an emphasis on achieving negative margins without loss of form or function, given the variability of chemosensitivity of such diverse tumors, it may be better to tailor the resection to histology for each patient.
If the initial operation fails to achieve pathologically negative tissue margins or if the initial surgery was done without the knowledge that cancer was present, a re-excision of the affected area is performed to obtain clear, but not necessarily wide, margins.[4-7] This surgical tenet is true even if no mass is detected by magnetic resonance imaging after initial surgery.[8]; [9][Level of evidence C1]
Sources: 4 · 7 · 8 · 9 · Level of evidence C1
Regional lymph node metastases at diagnosis are unusual and are most often seen in patients with epithelioid and clear cell sarcomas.[10,11] Sentinel lymph node biopsy as a staging procedure in soft tissue sarcoma remains controversial. However, it may help manage selected cases in adults with clear cell sarcoma and epithelioid sarcoma. There are insufficient data to support the use of sentinel lymph node biopsy in the management of pediatric patients with other NRSTS.[12-17]
Radiation Therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Considerations for radiation therapy are based on the potential for surgery, with or without chemotherapy, to obtain local control without severe injury to critical organs, compromise of function, or significant cosmetic or psychological impairment. This will vary according to the following:
Patient variables (e.g., age and sex).
Tumor variables (e.g., histopathology, site, size, and grade).
Surgery and subsequent margin status.
Expectations for radiation-induced morbidities (e.g., impaired bone or muscle development, organ damage, or subsequent neoplasms).
Radiation therapy can be given preoperatively or postoperatively. It can also be used as definitive therapy in rare situations in which surgical resection is not performed.[18] Radiation field size and dose will be based on patient and tumor variables and the surgical procedure.[19] Radiation therapy is associated with improved OS compared with surgery alone when delivered preoperatively or postoperatively.[20]
Brachytherapy and intraoperative radiation may be applicable in select situations.[21-23]; [24][Level of evidence C2]
Sources: 21 · 23 · 24 · Level of evidence C2
Preoperative radiation therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Preoperative radiation therapy has been associated with excellent local control rates.[25-27] The advantages of this approach include treating smaller tissue volumes without the need to treat a postsurgical bed and somewhat lower radiation doses because relative hypoxia from surgical disruption of vasculature and scarring is not present. Preoperative radiation therapy has been associated with an increased rate of wound complications in adults, primarily in lower extremity tumors. However, the degree of these complications is questionable.[28] Conversely, preoperative radiation therapy may lead to less fibrosis than with postoperative approaches, perhaps because of the smaller treatment volume and dose.[29] Radiation techniques, like proton-beam radiation therapy can facilitate normal tissue sparing. Compared with 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy may decrease radiation dose to the skin and epiphysis when irradiating extremity sarcomas, which can translate into decreased fibrosis or growth impairment.[30,31]
Sources: 25 · 27 · 28 · 29 · proton-beam radiation therapy · 3-dimensional conformal radiation therapy · intensity-modulated radiation therapy · 30 · 31
Postoperative radiation therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Radiation therapy can also be given postoperatively. In general, radiation is indicated for patients with inadequate surgical margins and for larger, high-grade tumors.[32,33] This is particularly important in high-grade tumors with tumor margins smaller than 1 cm.[34,35]; [36][Level of evidence C3] With combined R0 (negative margin) surgery and radiation therapy, local control of the primary tumor can be achieved in about 90% of patients with extremity sarcomas, 70% to 75% of patients with retroperitoneal sarcomas, and 80% of patients overall.[21,37-40]
Sources: 32 · 33 · 34 · 35 · 36 · Level of evidence C3 · 21 · 37 · 40
Retroperitoneal sarcomas are unique in that the radiosensitivity of the bowel increases the risk of injury and makes postoperative radiation therapy less desirable.[41,42] Postoperative adhesions and bowel immobility can increase the risk of damage from any given radiation dose. This contrasts with the preoperative approach in which the tumor often displaces bowel outside of the radiation field, and any exposed bowel is more mobile, which decreases exposure to specific bowel segments.
Dose and volume
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Radiation volume and dose depend on the patient, tumor, and surgical variables noted above, as well as the following:
Patient age and growth potential.
Ability to avoid critical organs, epiphyseal plates, and lymphatics (but not the neurovascular bundles that are relatively radiation tolerant).
Functional/cosmetic outcome.
Radiation doses are typically 45 Gy to 50 Gy preoperatively, and as high as 60 Gy to very small volumes at highest risk when postoperative resection margins are predicted to be microscopically or grossly positive. Planned brachytherapy is an option if the resection is predicted to be subtotal. This can be accomplished with a simultaneously integrated boost dose (i.e., higher dose area within the larger lower dose volume) or administered with a small field of radiation after the initial volume is treated with a dose of 45 Gy to 50 Gy. However, data documenting the efficacy of a postoperative boost to areas with microscopically positive margins are lacking.[43] The postoperative radiation dose is 55 Gy to 60 Gy for R0 resections, up to 65 Gy for R1 resections (microscopic positive margins), and higher when unresectable gross residual disease exists, depending on overall treatment goals (e.g., definitive local control vs. palliation).
Sources: 43
The COG analyzed local recurrence (LR) for NRSTS after radiation therapy in patients treated in the ARST0332 trial.[3] Patients younger than 30 years with high-grade NRSTS received radiation therapy (55.8 Gy) for an R1, 5 cm or smaller tumor (arm B); radiation therapy (55.8 Gy) with chemotherapy for an R0/R1, larger than 5 cm tumor (arm C); or neoadjuvant radiation therapy (45 Gy) with chemotherapy plus delayed surgery, chemotherapy, and postoperative boost to 10.8 Gy for an R0, smaller than 5 mm margins tumor or R1 tumor, or 19.8 Gy for R2 or unresected tumors (arm D).
Sources: 3
Of 193 eligible patients, 24 had local recurrences (arm B: 1 of 15 [6.7%], arm C: 7 of 65 [10.8%], arm D: 16 of 113 [14.2%]) with a median time to local recurrence of 1.1 years (range, 0.11–5.27 years).
Of 95 patients eligible for delayed surgery after neoadjuvant therapy, 89 (93.7%) achieved R0/R1 margins.
Overall local control after radiation therapy were as follows: R0, 106 of 109 (97%); R1, 51 of 60 (85%); and R2/unresectable, 2 of 6 (33%).
The authors concluded that risk-based treatment for young patients with high-grade NRSTS treated on ARST0332 produced very high local control, particularly after R0 resection (97%), despite lower-than-standard radiation therapy doses.
Radiation margins are typically 2 cm to 4 cm longitudinally and encompass fascial planes axially.[44,45]
Radiation therapy was used in the COG ARST1321 trial.
Sources: ARST1321
Chemotherapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
The role of postoperative chemotherapy remains unclear.[46]
Sources: 46
Evidence (lack of clarity regarding postoperative chemotherapy):
A meta-analysis of data from all randomized trials of adults with soft tissue sarcoma observed the following:[47]
Sources: 47
A meta-analysis of data from all randomized trials of adults with soft tissue sarcoma observed the following:[47]
Recurrence-free survival was better with postoperative chemotherapy for patients with high-grade tumors larger than 5 cm.
In a European trial, adults with completely resected soft tissue sarcoma were randomly assigned to observation or postoperative chemotherapy with ifosfamide and doxorubicin.[48][Level of evidence A1]
Sources: 48 · Level of evidence A1
In a European trial, adults with completely resected soft tissue sarcoma were randomly assigned to observation or postoperative chemotherapy with ifosfamide and doxorubicin.[48][Level of evidence A1]
Postoperative chemotherapy was not associated with improved EFS or OS.
It is difficult to extrapolate this trial to pediatric patients because the trial included: (1) a wide variety of histologies; (2) a relatively low dose of ifosfamide; (3) patients assigned to chemotherapy had definitive radiation delayed until completion of chemotherapy; and (4) almost one-half of the patients in the trial had intermediate-grade tumors.
In the discussion section, the authors merged their patients with previously published series, including those from the European meta-analysis, and concluded that the results suggested a benefit for postoperative chemotherapy.
The largest prospective pediatric trial failed to demonstrate any benefit with postoperative vincristine, dactinomycin, cyclophosphamide, and doxorubicin.[37]
Sources: 37
Doxorubicin and ifosfamide were used in the risk-based COG ARST0332 (NCT00346164) trial.[1][Level of evidence C1]
Sources: ARST0332 (NCT00346164) · 1 · Level of evidence C1
Doxorubicin and ifosfamide were used in the risk-based COG ARST0332 (NCT00346164) trial.[1][Level of evidence C1]
Although this was not a randomized study, results at 2.6 years showed that patients with high-risk (>5 cm and high grade), grossly resected, nonmetastatic tumors who were treated with radiation therapy and postoperative doxorubicin and ifosfamide had a 5-year EFS rate of 67.2% and an OS rate of 78%. However, this study did not have a comparison group of patients who did not receive chemotherapy.
In patients with metastatic disease treated with preoperative chemotherapy and radiation therapy, the estimated 5-year EFS rate was 21.2%, and the OS rate was 35.5%.
Targeted Therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
The use of angiogenesis and mammalian target of rapamycin (mTOR) inhibitors has been explored in the treatment of adult patients with soft tissue sarcomas but not in pediatric patients. Other targeted therapy agents are reported for specific tumor types in the following sections.
Evidence (targeted therapy in adults with soft tissue sarcoma):
In a trial of 711 adult patients who achieved a response or stable disease after chemotherapy, patients were randomly assigned to receive ridaforolimus (a rapamycin inhibitor) or placebo.[49]
Sources: 49
In a trial of 711 adult patients who achieved a response or stable disease after chemotherapy, patients were randomly assigned to receive ridaforolimus (a rapamycin inhibitor) or placebo.[49]
The administration of ridaforolimus was associated with a 3-week improvement in progression-free survival (PFS) when compared with placebo.
In another trial of 371 randomly assigned adult patients with metastatic soft tissue sarcoma that progressed after chemotherapy, pazopanib (a multitargeted receptor tyrosine kinase inhibitor) was compared with placebo.[50]
Sources: 50
In another trial of 371 randomly assigned adult patients with metastatic soft tissue sarcoma that progressed after chemotherapy, pazopanib (a multitargeted receptor tyrosine kinase inhibitor) was compared with placebo.[50]
The median PFS for the pazopanib arm was 4.6 months, compared with 1.6 months for the placebo arm. OS was not different between the two arms.
In a study of 182 previously treated adult patients with recurrent liposarcoma, leiomyosarcoma, synovial sarcoma, and other sarcomas, patients were randomly assigned to receive either regorafenib or placebo.[51]
Sources: 51
In a study of 182 previously treated adult patients with recurrent liposarcoma, leiomyosarcoma, synovial sarcoma, and other sarcomas, patients were randomly assigned to receive either regorafenib or placebo.[51]
Patients with nonadipocytic tumors who were treated with regorafenib had significant improvements in PFS when compared with patients who were treated with placebo.
The COG and NRG Oncology cancer consortia conducted a randomized trial of pazopanib added to neoadjuvant chemotherapy (doxorubicin and ifosfamide) and preoperative radiation therapy in pediatric (older than 2 years) and adult patients with NRSTS. Patients with intermediate- or high-grade disease whose tumors were larger than 5 cm were eligible. The end point of the trial was pathological tumor response after adjuvant therapy. Study entry was closed early because the planned interim analysis showed that the pathological response boundary was crossed. Eighty-one patients were enrolled, but only 42 (52%) were available for response data (17 patients from each group discontinued therapy for either progression, unacceptable toxicity, or patient or physician choice).[52,53]
The COG and NRG Oncology cancer consortia conducted a randomized trial of pazopanib added to neoadjuvant chemotherapy (doxorubicin and ifosfamide) and preoperative radiation therapy in pediatric (older than 2 years) and adult patients with NRSTS. Patients with intermediate- or high-grade disease whose tumors were larger than 5 cm were eligible. The end point of the trial was pathological tumor response after adjuvant therapy. Study entry was closed early because the planned interim analysis showed that the pathological response boundary was crossed. Eighty-one patients were enrolled, but only 42 (52%) were available for response data (17 patients from each group discontinued therapy for either progression, unacceptable toxicity, or patient or physician choice).[52,53]
Four of 18 patients (22%) in the control group had greater than 90% necrosis at resection, compared with 14 of 24 patients (58%) in the group treated with pazopanib, meeting the criteria for early stopping of the study.
Toxicity was greater in the pazopanib group, mainly resulting from increased myelosuppression. Wound complications were also more frequent in the pazopanib group.
With longer follow-up, the investigators were able to analyze the secondary objectives of OS and EFS.[54] At a median follow-up of 3.3 years (range, 0.1–5.8 years), the 3-year EFS rate for all patients in the intent-to-treat analysis was 52.5% for patients who received pazopanib and 50.6% for those who did not (log-rank P = .8677). The 3-year OS rate was 75.7% for patients who received pazopanib and 65.4% for the control group (log-rank P = .1919). However, the study was not powered to evaluate these end points.
Sources: 54
Special Considerations for the Treatment of Children With Soft Tissue Sarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 1
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Multidisciplinary evaluation in pediatric cancer centers that have surgical and radiotherapeutic expertise is of critical importance to ensure the best clinical outcome for these patients. Although surgery with or without radiation therapy can be curative for a significant proportion of patients, the addition of chemotherapy might benefit subsets of children with the disease. Therefore, enrollment in clinical trials is encouraged. Clinical trials for children and adolescents with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 2 · NCI website
Many therapeutic strategies for children and adolescents with soft tissue tumors are similar to those for adult patients, although there are important differences. For example, the biology of the neoplasm in pediatric patients may differ dramatically from that of the adult lesion. Additionally, limb-sparing procedures are more difficult to perform in pediatric patients. The morbidity associated with radiation therapy, particularly in infants and young children, may be much greater than that observed in adults.[3]
Sources: 3
Improved outcomes with multimodality therapy in adults and children with soft tissue sarcomas over the past 20 years have caused increasing concern about the potential long-term side effects of this therapy in children. To maximize tumor control and minimize long-term morbidity, treatment must be individualized for children and adolescents with nonrhabdomyosarcomatous soft tissue sarcoma. These patients should be enrolled in prospective studies that accurately assess any potential complications.[4]
Sources: 4
Treatment of Adipocytic Tumors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Adipocytic tumors account for less than 10% of soft tissue lesions in patients younger than 20 years. The most common adipocytic tumors in children are lipomas and lipoblastomas.
Table 11 summarizes the adipocytic neoplasms seen in pediatric patients and includes information about their corresponding clinico-pathological and molecular features.[1]
Content omitted from this reproduction: Source contains an explicit third-party copyright/reprint notice. Text/table excluded from production import; original remains in raw audit and linked NCI source.. Follow the source link to read the original.
Sources: 2 · 3 · Seminars in Diagnostic Pathology · 1 · 4 · 4 · 5 · 6
Liposarcoma, Well-Differentiated, Not Otherwise Specified (NOS)
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Liposarcoma is rare in the pediatric population and accounts for 3% of soft tissue sarcoma in patients younger than 20 years (see Table 1).
Sources: Table 1
In a review of 182 pediatric patients with adult-type sarcomas, only 14 had a diagnosis of liposarcoma.[7] One retrospective study identified 34 patients younger than 22 years from 1960 to 2011.[8] There were roughly equal numbers of male and female patients, and the median age was 18 years. In an international clinico-pathological review, the characteristics of 82 cases of pediatric liposarcoma were reported.[9] The median age was 15.5 years, and females were more commonly affected. In both reports, most patients had myxoid liposarcoma.[8,9]
A literature review of 275 cases of pediatric liposarcoma showed that:[10]
Sources: 10
Myxoid liposarcoma was the most common histology (68%), followed by well-differentiated liposarcoma (10.5%).
Twelve percent of patients died of disease, and most of the deaths occurred in patients with the pleomorphic and myxoid pleomorphic subtypes.
About 70% of patients with myxoid and well-differentiated liposarcoma were treated with surgery only. The overall clinical outcomes for these groups of patients were excellent, with no evidence of disease in 114 of 127 patients.
In contrast, more than 50% of patients with pleomorphic liposarcoma received radiation therapy and chemotherapy in addition to surgery, and their clinical outcome was suboptimal, with no evidence of disease in only 5 of 10 patients.
Germline TP53 pathogenic variants were seen in two patients with myxoid pleomorphic liposarcoma and two patients with well-differentiated liposarcoma who had a family history compatible with Li-Fraumeni syndrome.
Clinical presentation
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Most liposarcomas in the pediatric and adolescent age range are low grade and located subcutaneously. Metastasis to lymph nodes is uncommon, and most metastases are pulmonary. Tumors arising in the periphery are more likely to be low grade and myxoid. Tumors arising centrally are more likely to be high grade, pleomorphic, and present with metastasis or recur with metastasis.
Histopathological classification
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
The World Health Organization (WHO) classification for liposarcoma is as follows:[11]
Sources: 11
Intermediate (locally aggressive).
Intermediate (locally aggressive).
Atypical lipomatous tumor. These tumors do not metastasize unless they undergo dedifferentiation.
Malignant.
Malignant.
Dedifferentiated liposarcoma.
Myxoid liposarcoma. Pure myxoid liposarcomas are characterized by a t(12;16)(q13;p11) translocation and can metastasize, but patients usually have an excellent outcome when they do not have a round cell component.[12] Myxoid liposarcoma is the most common subtype of liposarcoma in the pediatric population.[8,9]
Pleomorphic liposarcoma. This is an uncommon type of liposarcoma and primarily arises in older adults.
Myxoid pleomorphic liposarcoma. This rare entity occurs primarily in children, adolescents, and young adults. It commonly presents in the mediastinum and is clinically aggressive.
Liposarcoma, well-differentiated, NOS.
Genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Atypical lipomatous tumor. This entity is characterized by supernumerary ring and giant marker chromosomes that contain chromosomal region 12q14-q15, which includes MDM2. MDM2 amplification can be detected in virtually all cases of atypical lipomatous tumor/well-differentiated liposarcoma, with nearby genes such as CDK4 and FRS2 commonly being coamplified with MDM2.[13]
Sources: 13
Dedifferentiated liposarcoma. This entity, like atypical lipomatous tumor, is characterized by MDM2 amplification and the supernumerary ring and giant marker chromosomes containing the chromosomal region 12q14-q15. Dedifferentiated liposarcoma contains a high number of segmental copy number alterations, but has few gene variants.[14]
Sources: 14
Myxoid liposarcoma. This entity is characterized by the t(12;16)(q13;p11) translocation that produces the FUS::DDIT3 gene fusion.[14] In a small percentage of cases, EWSR1 substitutes for FUS, producing the EWSR1::DDIT3 gene fusion (t(12;22)(q13;q12)). DDIT3 (previously called CHOP and GADD153) is a stress-induced gene that has an inhibitory effect on adipogenesis.[15] Myxoid liposarcoma is the most common subtype of liposarcoma in the pediatric population. Most pediatric cases show the FUS::DDIT3 gene fusion.[8,9,16]
Pleomorphic liposarcoma. This entity is primarily a disease of older adults and lacks either DDIT3 gene rearrangements or MDM2 amplification. Cases of pleomorphic liposarcoma typically have multiple chromosomal imbalances, including variants in TP53 and NF1 observed in some cases.[17]
Sources: 17
Myxoid pleomorphic liposarcoma. This entity most commonly presents in the adolescent and young adult population and lacks the DDIT3 gene rearrangement of myxoid liposarcoma and the MDM2 amplification of atypical lipomatous tumor and dedifferentiated liposarcoma.[9,16,18] Instead, myxoid pleomorphic liposarcoma presents with multiple chromosomal gains and losses. Loss of Rb expression is commonly observed, sometimes in association with loss of chromosome 13q14 where RB1 is located.[18,19] Although most cases of myxoid pleomorphic liposarcoma lack TP53 variants, a minority have TP53 variants that are associated with Li-Fraumeni syndrome in some cases.[20-22]
Prognosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Higher grade or central tumors are associated with a significantly higher risk of death. In an international retrospective review, the 5-year survival rate was 42% for patients with central tumors. Seven of ten patients with pleomorphic myxoid liposarcoma died of their disease.[9] In a retrospective study of 14 patients, the 5-year survival rate was 78%. Tumor grade, histological subtype, and primary location correlated with survival.[8]
Treatment of liposarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for liposarcoma include the following:
Surgery. If the tumor is not completely removed or locally recurs, a second surgery may be performed.[23-25]
Chemotherapy followed by surgery.
Sources: Chemotherapy
Surgery and radiation therapy (evidence based on adult studies).[26,27]
Sources: Surgery and radiation therapy · 26 · 27
Targeted therapy (evidence based on adult studies).[28]
Sources: Targeted therapy · 28
Surgery
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Surgery is the most important treatment for liposarcoma. After complete surgical resection of well-differentiated or myxoid liposarcoma, the event-free survival (EFS) and overall survival (OS) rates are roughly 90%.[29] If initial surgery is incomplete, re-excision should be performed to achieve a wide margin of resection.[23-25] Local recurrences have been seen and are controlled with a second resection of the tumor, particularly for low-grade liposarcomas.
Chemotherapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Chemotherapy has been used to decrease the size of liposarcoma before surgery to facilitate complete resection, particularly in central tumors.[30,31] The role of postoperative chemotherapy for liposarcoma is poorly defined. Postoperative therapy for completely resected myxoid liposarcomas does not appear to be needed. Even with the use of postoperative chemotherapy, the survival of patients with pleomorphic liposarcomas remains poor.[32]
There are limited data to support the use of trabectedin in pediatric patients.[33] Trabectedin has produced encouraging responses in adults with advanced myxoid liposarcoma.[34] In one study, adult patients with recurrent liposarcoma and leiomyosarcoma were randomly assigned to treatment with either trabectedin or dacarbazine. Patients treated with trabectedin had a 45% reduction in disease progression.[35][Level of evidence B1]
Sources: 33 · 34 · 35 · Level of evidence B1
Treatment with eribulin, a nontaxane microtubule dynamics inhibitor, significantly improved survival in adult patients with recurrent liposarcoma compared with dacarbazine. The median OS was 15.6 months for patients who received eribulin, versus 8.4 months for patients who received dacarbazine. Survival differences were more pronounced in patients with dedifferentiated and pleomorphic liposarcoma. Eribulin was effective in prolonging survival of patients with either high-grade or intermediate-grade tumors.[36][Level of evidence A1] A pediatric phase I trial of eribulin did not accrue any patients with liposarcoma.[37]
Sources: 36 · Level of evidence A1 · 37
Surgery and radiation therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Targeted therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
In a phase II, single-arm, multicenter study, 41 adult patients with unresectable or metastatic high-grade or intermediate-grade liposarcoma were treated with pazopanib at a dose of 800 mg daily.[28][Level of evidence B4]
Sources: 28 · Level of evidence B4
The progression-free survival (PFS) rate at 12 weeks was 68.3%, which was significantly greater than the null hypothesis value of 40%.
Forty-four percent of patients experienced tumor control. One patient had a partial response, and 17 patients had stable disease.
At 24 weeks, 39% of the patients remained progression free. The median PFS was 4.4 months, and median OS was 12.6 months.
Treatment of Chondro-osseous Tumors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Chondro-osseous tumors have several subtypes, including the following:
Extraskeletal mesenchymal chondrosarcoma.
Osteosarcoma, extraskeletal.
Sources: Osteosarcoma, extraskeletal
Extraskeletal Mesenchymal Chondrosarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Osseous and chondromatous neoplasms account for 0.8% of soft tissue sarcomas in patients younger than 20 years (see Table 1). Mesenchymal chondrosarcoma is more common in the head and neck region.
Sources: Table 1
Histopathological features and genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Mesenchymal chondrosarcoma is a rare tumor characterized by small round cells and hyaline cartilage, and it more commonly affects young adults.
Mesenchymal chondrosarcoma has been associated with a consistent chromosomal rearrangement. A retrospective analysis of cases of mesenchymal chondrosarcoma identified a HEY1::NCOA2 gene fusion in 10 of 15 tested specimens.[1] This gene fusion was not associated with chromosomal changes that could be detected by karyotyping. In one instance, translocation t(1;5)(q42;q32) was identified in a case of mesenchymal chondrosarcoma and shown to be associated with a novel IRF2BP::CDX1 gene fusion.[2]
A retrospective study analyzed 13 patients with mesenchymal chondrosarcoma, all with confirmed HEY1::NCOA2 gene fusions.[3]
Sources: 3
The median age of presentation was 19 years.
Five patients with mesenchymal chondrosarcomas (39%) had an intraosseous presentation (skull, maxilla, palate, and mandible), while the remaining eight cases occurred in the brain/meninges, orbit, and nasal cavity.
Microscopically, head and neck mesenchymal chondrosarcomas were characterized by primitive round cells arranged in a distinctive nested architecture and a rich staghorn vasculature.
A cartilaginous component of hyaline cartilage islands and/or single chondrocytes were present in 69% of cases.
A combined immunoprofile of CD99(+)/SATB2(+)/CD34(-)/STAT6(-) was typically noted.
Prognostic factors and prognosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
A retrospective survey of European institutions identified 113 children and adults with mesenchymal chondrosarcoma. Factors associated with better outcomes included the following:[4][Level of evidence C1]
Sources: 4 · Level of evidence C1
Lack of metastatic disease at initial presentation.
Clear resection margins.
Administration of postoperative chemotherapy after resection for patients with initially localized disease.
A retrospective analysis of Surveillance, Epidemiology, and End Results (SEER) Program data from 1973 to 2011 identified 205 patients with mesenchymal chondrosarcoma; 82 patients had skeletal primary tumors, and 123 patients had extraskeletal tumors.[5] The outcomes of patients with skeletal and extraskeletal primary tumors were the same. Factors associated with outcomes included the following:
Sources: 5
Primary site: The 5-year overall survival (OS) rate was 50% for patients with appendicular tumors, 37% for patients with axial tumors, and 74% for patients with cranial tumors.
Metastases and tumor size: Presence of metastatic disease and larger tumor size were independently associated with an increased risk of death.
A single-institution retrospective review identified 43 cases of mesenchymal chondrosarcoma from 1979 to 2010.[6] Thirty patients with localized disease were evaluated. The mean age at diagnosis was 33 years (range, 11–65 years).
Sources: 6
The 5-year OS rate was 51%, and the 10-year OS rate was 37%.
Younger age (<30 years) and male sex were associated with poorer OS and disease-free survival (DFS).
Patients who did not receive adjuvant radiation therapy were more likely to have a local recurrence.
Treatment of extraskeletal mesenchymal chondrosarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for extraskeletal mesenchymal chondrosarcoma include the following:
Surgery.
Chemotherapy followed by surgery and additional chemotherapy. Radiation therapy may also be given.
A review of 15 patients younger than 26 years included 11 patients with soft tissue lesions from the German Cooperative Soft Tissue Sarcoma Study Group and 4 patients with primary bone lesions from the German-Austrian-Swiss Cooperative Osteosarcoma Study Group protocols. The review suggested that complete surgical removal, or incomplete resection followed by radiation therapy, was necessary for local control.[9][Level of evidence C1]
Sources: 9 · Level of evidence C1
A single-institution, retrospective review identified 12 pediatric patients with mesenchymal chondrosarcoma.[10] Eleven patients presented with localized disease, and one patient presented with pulmonary nodules. Six patients received preoperative chemotherapy. All patients received postoperative chemotherapy (most commonly ifosfamide/doxorubicin) with or without radiation therapy (median dose, 59.4 Gy).
Sources: 10
The NCOA2 rearrangement was documented in these patients' tumors.
The study confirmed that surgical resection is necessary for cure.
At a median follow-up of 4.8 years, the 5-year DFS rate was 68.2% (95% confidence interval [CI], 39.8%–96.6%), and the OS rate was 88.9% (95% CI, 66.9%–100%).
A Japanese study of patients with extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma randomly assigned patients to treatment with either trabectedin or best supportive care.[11] The median age of patients was 38 years (range, 21–77 years).
Sources: 11
The OS was higher for the patients assigned to receive trabectedin than for patients assigned to receive best supportive care.
Osteosarcoma, Extraskeletal
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Extraskeletal osteosarcoma is extremely rare in the pediatric and adolescent population. Osseous and chondromatous neoplasms account for 0.8% of soft tissue sarcomas in patients younger than 20 years (see Table 1).
Sources: Table 1
Genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
A review of 32 adult patients with extraskeletal osteosarcomas consistently revealed several alterations.[12] Frequent genomic alterations included copy number losses in CDKN2A (70%), TP53 (56%), and RB1 (49%). Variants were identified that affected methylation/demethylation (40%), chromatin remodeling (27%), and the WNT/SHH pathways (27%). Cases with simultaneous TP53 and RB1 biallelic copy number losses were associated with worse DFS and OS.
Sources: 12
Prognostic factors and prognosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Extraskeletal osteosarcoma is associated with a high risk of local recurrence and pulmonary metastasis.[13]
Sources: 13
A single-institution retrospective review identified 43 patients with extraskeletal osteosarcoma; 37 patients had localized disease, and 6 patients presented with metastatic disease. The median age was 55 years (range, 7–81 years). Seventy-five percent of patients received chemotherapy.[14]
Sources: 14
The median progression-free survival (PFS) was 21 months.
The median OS was 50 months.
There was a trend toward better survival for patients who received chemotherapy, and a statistically significant improvement in survival for patients who received chemotherapy that included cisplatin.
In a review of 274 patients with extraskeletal osteosarcoma, the median age at diagnosis was 57 years (range, 12–91 years).[15][Level of evidence C1]
Sources: 15 · Level of evidence C1
The 5-year DFS and OS rates were significantly better for those who received chemotherapy.
The use of an osteosarcoma-type regimen was associated with improved response rates.
The European Musculoskeletal Oncology Society performed a retrospective analysis of 266 eligible patients with extraskeletal osteosarcoma treated between 1981 and 2014. Fifty patients (19%) presented with metastatic disease.[15]
Sources: 15
An analysis of the 211 patients who achieved complete remission after surgical resection of the primary tumor showed a 5-year OS rate of 51% and a DFS rate of 43%.
There was a favorable trend for survival among patients who were treated with chemotherapy that is usually employed for patients with osseous osteosarcoma.
In a multivariable analysis, factors associated with better prognosis included younger age (<40 years), smaller tumors, and use of chemotherapy.
An analysis of SEER Program data from 1973 to 2009 identified 256 patients (6%) with extraskeletal osteosarcoma among 4,173 patients with high-grade osteosarcoma.[16]
Sources: 16
Compared with skeletal osteosarcoma, patients with extraskeletal osteosarcoma were more likely to be older, female, have an axial primary tumor, and have regional lymph node involvement.
Adverse prognostic features included presence of metastatic disease, larger tumor size, older age, and axial primary tumor site.
Treatment of extraskeletal osteosarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for extraskeletal osteosarcoma include the following:
Typical chemotherapy regimens used for osteosarcoma include some combination of cisplatin, doxorubicin, high-dose methotrexate, and ifosfamide.[13-15]
For more information about the treatment of extraosseous osteosarcoma, including chemotherapy options, see Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment.
Sources: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment
Treatment of Fibroblastic and Myofibroblastic Tumors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Fibroblastic and myofibroblastic tumors have several subtypes, including the following:
Intermediate (locally aggressive).
Intermediate (locally aggressive).
Desmoid-type fibromatosis (previously called desmoid tumor or aggressive fibromatoses).
Sources: Desmoid-type fibromatosis
Intermediate (rarely metastasizing).
Intermediate (rarely metastasizing).
Dermatofibrosarcoma protuberans not otherwise specified (NOS).
Sources: Dermatofibrosarcoma protuberans not otherwise specified (NOS)
Inflammatory myofibroblastic tumor.
Sources: Inflammatory myofibroblastic tumor
Intermediate (rarely metastasizing). › Inflammatory myofibroblastic tumor.
Epithelioid inflammatory myofibroblastic sarcoma.
Malignant.
Myxofibrosarcoma.
Sources: Myxofibrosarcoma
Low-grade fibromyxoid sarcoma.
Sources: Low-grade fibromyxoid sarcoma
Sclerosing epithelioid fibrosarcoma.
Sources: Sclerosing epithelioid fibrosarcoma
Desmoid-Type Fibromatosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Desmoid-type fibromatosis has previously been called desmoid tumor or aggressive fibromatosis.
Desmoid-type fibromatosis has an extremely low potential to metastasize. The tumors are locally infiltrating, and surgical control can be challenging because of difficulty obtaining margins of resection that contain the entire infiltrating tumor.
Genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Most desmoid tumors are sporadic, but a small proportion may occur in association with a variant in the APC gene (associated with intestinal polyps and a high incidence of colon cancer). In a study of 519 patients older than 10 years with a diagnosis of desmoid-type fibromatosis, 39 patients (7.5%, a possible underestimation) were found to have familial adenomatous polyposis (FAP).[3] The patients with FAP and desmoid-type fibromatosis were younger, more often male, and had more abdominal wall or mesenteric tumors than did patients with desmoid-type fibromatosis without FAP.
Sources: 3
Variants in exon 3 of the CTNNB1 gene are seen in more than 80% of desmoid-type fibromatosis cases. The 45F variant in exon 3 of the CTNNB1 gene has been associated with an increased risk of disease recurrence.[4]
Sources: 4
Currently, there are no general recommendations for genetic testing in children with desmoid-type fibromatosis. Pathological and molecular characteristics of the tumor only provide guidance for screening.
A patient should be referred to a genetic counselor if there is a family history of colon cancer, congenital hyperplasia of the retinal pigment epithelium is present,[5,6] or the desmoid-type fibromatosis occurs in the abdomen or abdominal wall.[3] If the tumor has a somatic CTNNB1 variant, screening is not necessary, because the APC gene variant has not been described in this setting. If a CTNNB1 variant is not identified, screening for the APC variant may be warranted.[7,8]
Pediatric desmoid tumors can harbor additional variants in the AKT, BRAF V600E, TP53, and RET genes.[9] For more information, see the Familial Adenomatous Polyposis (FAP) section in Genetics of Colorectal Cancer.
Sources: 9 · Familial Adenomatous Polyposis (FAP)
Treatment of desmoid-type fibromatosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Evaluating the benefit of treatment interventions for desmoid-type fibromatosis has been extremely difficult, because desmoid-type fibromatosis has a highly variable natural history, with partial regressions seen in up to 20% of patients.[2] Large adult series and smaller pediatric series have reported long periods of disease stabilization and even regression without systemic therapy.[10,11]; [12][Level of evidence C2] For instance, in a large placebo-controlled trial of sorafenib in adult patients with desmoid tumors, the patients who received no therapy (observation/placebo) demonstrated a 20% partial regression rate, and 46% of the patients in the placebo group had no progression at 1 year.[2]
Treatment options for desmoid-type fibromatosis include the following:
Observation.
Sources: Observation
Chemotherapy, for unresectable or recurrent tumors.
Tyrosine kinase inhibitors.
Sources: Tyrosine kinase inhibitors
NOTCH pathway/gamma-secretase inhibitors.
Nonsteroidal anti-inflammatory drugs (NSAIDS).
Antiestrogen treatment.
Sources: Antiestrogen treatment
Surgery.
Sources: Surgery
Radiation therapy.
Sources: Radiation therapy
Observation
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Because of the variable natural history of desmoid tumors, as outlined above, observation is sometimes a viable option. This is particularly the case for lesions that are asymptomatic, do not pose a danger to vital organs, or are incompletely resected.[11,13-19]
A global consensus meeting that involved sarcoma experts with experience in both adult and pediatric desmoid tumor was organized to define the appropriate management of these tumors. The Desmoid Tumor Working Group suggested that an initial active surveillance approach does not influence the efficacy of subsequent treatments. They suggested that active therapy should only be considered in cases of persistent progression or symptoms. Active surveillance includes continuous monitoring with a first magnetic resonance imaging within 1 to 2 months of diagnosis, followed by scans in 3- to 6-month intervals. When the disease is located in critical structures that may pose significant morbidity, such as the mesentery and head and neck region, earlier treatment decisions should be made.[20]
Sources: 20
Evidence (observation vs. initial surgery):
A nonrandomized prospective cohort study included 771 patients with desmoid-type fibromatosis who were referred for second opinion and molecular analysis from 22 referral centers in France. The study compared initial surgery with initial observation.[21][Level of evidence C2]
Sources: 21 · Level of evidence C2
A nonrandomized prospective cohort study included 771 patients with desmoid-type fibromatosis who were referred for second opinion and molecular analysis from 22 referral centers in France. The study compared initial surgery with initial observation.[21][Level of evidence C2]
There was no difference in event-free survival (EFS) rates between the two groups (53% vs. 58%; P = .415).
Among patients with favorable tumor locations (defined as abdominal wall, intra-abdominal, breast, digestive viscera, and lower limb), the 2-year EFS rate was similar in patients who underwent surgery (70%) or were observed (63%; P = .41).
Among patients with tumors in unfavorable locations (defined as chest wall, head and neck, and upper limb), the 2-year EFS rate was significantly better for those treated nonsurgically (52%) compared with those who underwent initial surgery (25%; P = .001).
There were 173 patients with desmoid-type fibromatosis who were treated on European paediatric Soft Tissue Sarcoma Study Group (EpSSG) studies since 2005. Thirteen patients (8%) had biopsies only (no further treatment), 65 patients (42%) received chemotherapy only, 31 patients (20%) underwent surgery only, 36 patients (23%) had both chemotherapy and surgery, and 9 patients (6%) received radiation therapy in addition to other therapies.[22][Level of evidence C2]
Sources: 22 · Level of evidence C2
There were 173 patients with desmoid-type fibromatosis who were treated on European paediatric Soft Tissue Sarcoma Study Group (EpSSG) studies since 2005. Thirteen patients (8%) had biopsies only (no further treatment), 65 patients (42%) received chemotherapy only, 31 patients (20%) underwent surgery only, 36 patients (23%) had both chemotherapy and surgery, and 9 patients (6%) received radiation therapy in addition to other therapies.[22][Level of evidence C2]
All patients were alive at the time of analysis.
The authors concluded that the conservative nonsurgical approach did not compromise outcome in pediatric patients.
Chemotherapy, for unresectable or recurrent tumors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
The following chemotherapy regimens have been used to treat desmoid-type fibromatosis:
Methotrexate and vinblastine: This combination produced objective responses in about one-third of patients with unresectable or recurrent desmoid-type fibromatosis.[23]
Sources: 23
Doxorubicin and dacarbazine: A series of mainly adult patients with FAP and unresectable desmoid-type fibromatosis that were unresponsive to hormone therapy showed that doxorubicin plus dacarbazine followed by meloxicam (an NSAID) can be safely administered and can induce responses.[24]
Sources: 24
Pegylated liposomal doxorubicin: In a study of 11 patients, 4 patients achieved an objective response and 7 patients had stable disease.[25] In a series of five patients, a median progression-free interval of 29 months was reported.[26]
Hydroxyurea: A retrospective analysis reported the results of 16 children with previously treated desmoid tumors who were treated with hydroxyurea. Before hydroxyurea, seven patients had tumor progression, two patients had increased pain, and seven patients had both. Tumor shrinkage occurred in 37.5% of patients (with 18.7% partial remissions), and symptom improvement occurred in 68.7% of patients.[27]
Sources: 27
Vinorelbine: A retrospective review of 24 patients with desmoid-type fibromatosis (median age, 13.9 years; range, 1–23 years) received oral vinorelbine at eight centers of the Société Française des Cancers de l'Enfant between 2005 and 2020. For the 23 evaluable patients, 13% had partial responses, 78% had disease stabilization, and 9% had disease progression. The progression-free survival (PFS) rate was 89.3% at 24 months.[28]
Sources: 28
Tyrosine kinase inhibitors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Targeted therapy has been used to treat children and adults with desmoid-type fibromatosis.
Evidence (sorafenib):
An international, prospective, phase III, double-blind study was conducted through the National Clinical Trials Network to evaluate the efficacy of sorafenib in patients with unresectable progressive or symptomatic desmoid tumors. Eighty-seven patients were enrolled (aged 18–72 years). Patients were randomly assigned in a 2:1 fashion to receive either sorafenib or placebo. Crossover to sorafenib was permitted after disease progression.[2][Level of evidence B1]
Sources: 2 · Level of evidence B1
An international, prospective, phase III, double-blind study was conducted through the National Clinical Trials Network to evaluate the efficacy of sorafenib in patients with unresectable progressive or symptomatic desmoid tumors. Eighty-seven patients were enrolled (aged 18–72 years). Patients were randomly assigned in a 2:1 fashion to receive either sorafenib or placebo. Crossover to sorafenib was permitted after disease progression.[2][Level of evidence B1]
The objective response rate was 33% (95% confidence interval [CI], 20%–48%) in the sorafenib arm and 20% (95% CI, 8%–38%) in the placebo arm.
The median time to objective response was 9.5 months for patients treated with sorafenib and 13.3 months for patients who received the placebo.
The 2-year PFS rate was 81% for patients treated with sorafenib, compared with 36% for patients who received the placebo.
Evidence (pazopanib):
One small series included six patients (aged 3–21 years) with desmoid-type fibromatosis who were treated with pazopanib.[29]
Sources: 29
One small series included six patients (aged 3–21 years) with desmoid-type fibromatosis who were treated with pazopanib.[29]
Symptomatic improvement and stable disease were reported in all patients.
A randomized noncomparative study included adult patients with desmoid tumors who were treated with either pazopanib or methotrexate/vinblastine.[30]
Sources: 30
A randomized noncomparative study included adult patients with desmoid tumors who were treated with either pazopanib or methotrexate/vinblastine.[30]
About 84% of the patients who received pazopanib had no progression at 6 months.
NOTCH pathway/gamma-secretase inhibitors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
The NOTCH pathway has been implicated in the development of desmoid tumors.[31] The NOTCH pathway/gamma-secretase inhibitor nirogacestat has been evaluated in adult and pediatric patients.
Sources: 31
Evidence (nirogacestat):
One study included 17 adult patients with desmoid tumors, 15 of whom had variants in the APC or CTNNB1 genes.[32][Level of evidence C3]
Sources: 32 · Level of evidence C3
One study included 17 adult patients with desmoid tumors, 15 of whom had variants in the APC or CTNNB1 genes.[32][Level of evidence C3]
Five patients (29%) achieved a confirmed partial response to nirogacestat.
Four adult patients experienced grade 1 irregular menstruation.
In a clinical trial (NCT03785964), 75% of women of childbearing potential reported events related to ovarian dysfunction.[33]
Sources: NCT03785964 · 33
A small series included four patients younger than 20 years who received nirogacestat on a compassionate basis.[34][Level of evidence C3]
Sources: 34 · Level of evidence C3
A small series included four patients younger than 20 years who received nirogacestat on a compassionate basis.[34][Level of evidence C3]
Three patients had a durable benefit, defined as a complete response (n = 1), partial response (n = 1), or stable disease (n = 1).
No patients experienced grades 3 or 4 adverse events.
The U.S. Food and Drug Administration (FDA) approved nirogacestat for the treatment of patients aged 18 years and older with progressive desmoid tumors who require systemic therapy. The approval was based on a prospective, randomized, placebo-controlled trial conducted by a consortium.[33]
Sources: 33
The U.S. Food and Drug Administration (FDA) approved nirogacestat for the treatment of patients aged 18 years and older with progressive desmoid tumors who require systemic therapy. The approval was based on a prospective, randomized, placebo-controlled trial conducted by a consortium.[33]
In 142 patients, nirogacestat had a significant PFS benefit over placebo (hazard ratio for disease progression or death, 0.29; 95% CI, 0.15–0.55; P < .001).
The likelihood of being event free at 2 years was 76% with nirogacestat and 44% with placebo.
Nirogacestat was associated with significant benefits related to PFS, objective response, pain, symptom burden, physical functioning, role functioning, and health-related quality of life in adults with progressing desmoid tumors.
Nirogacestat was associated with a significant risk of ovarian failure.
NSAIDs
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
NSAIDs such as sulindac have been used in single cases for desmoid-type fibromatosis. The responses seen were usually disease stabilization.[35]
Sources: 35
Antiestrogen treatment
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Antiestrogen treatment, usually tamoxifen, plus sulindac has also resulted in disease stabilization.[36] A prospective trial of the combination of tamoxifen and sulindac reported few side effects, although asymptomatic ovarian cysts were common in girls. This combination showed relatively little activity, as measured by rates of response and PFS.[37][Level of evidence B4]
Sources: 36 · 37 · Level of evidence B4
Surgery
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Surgical resection should be used judiciously in patients with desmoid tumors because spontaneous regression can occur in up to 20% of cases. Surgical resection is recommended when tumor enlargement threatens the airway or when symptoms such as pain are persistent. A watch-and-wait strategy is otherwise preferred.
If surgery is chosen, the intent is to achieve clear margins. However, a retrospective review of children who underwent surgery for desmoid-type fibromatosis at St. Jude Children’s Research Hospital (SJCRH) reported no correlation between surgical margins and risk of recurrence.[19] In this study, 10 of 39 patients experienced a recurrence after surgery, with a median interval time of 2.5 years.
Sources: 19
Radiation therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Radiation has been used for unresectable and symptomatic desmoid-type fibromatosis or postoperatively for tumors with inadequate resections if progression would have morbid consequences. The potential long-term complications of radiation therapy, especially subsequent neoplasms, make this modality less appealing in younger patients.[38]
Sources: 38
Postoperative radiation therapy can be considered when recurrence or progression would entail additional surgery that might cause functional or cosmetic compromise and if radiation is considered acceptable in terms of morbidities.
Treatment options under clinical evaluation
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Dermatofibrosarcoma Protuberans NOS
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Dermatofibrosarcoma is a rare tumor that can be present in all age groups, but many of the reported cases arise in children.[39-41] A review of 451 cases in children younger than 20 years in the SEER Program database found that the incidence was 1 case per 1 million. The incidence was highest among Black patients aged 15 to 19 years. The most common sites were the trunk and extremities, which is similar to what is found in adults.
Ninety-five percent of patients underwent surgery. The overall survival (OS) rate was 100% at 5 years, 98% at 15 years, and 97% at 30 years. Male patients had decreased survival compared with female patients (P < .05).[42][Level of evidence C1]
Sources: 42 · Level of evidence C1
Genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
The tumor has a consistent chromosomal translocation t(17;22)(q22;q13) that juxtaposes the COL1A1 gene with the PDGFRB gene.
Treatment of dermatofibrosarcoma protuberans
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Guidelines for workup and management of dermatofibrosarcoma protuberans have been published.[43]
Sources: 43
Treatment options for dermatofibrosarcoma protuberans include the following:
Surgery with or without radiation therapy.
Targeted therapy (imatinib).
Sources: Targeted therapy (imatinib)
Surgery with or without radiation therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Most patients with dermatofibrosarcoma tumors can be cured by complete surgical resection. Wide excision with negative margins or Mohs/modified-Mohs surgery will prevent most tumors from recurring.[44] Despite the locally aggressive behavior of the tumor, lymph node or visceral metastasis rarely occurs.
Sources: 44
Evidence (surgery):
The EpSSG prospective NRSTS 2005 (NCT00334854) trial identified 46 patients with dermatofibrosarcoma protuberans.[45] The median age at diagnosis was 6.9 years (range, 0.4–17.5 years). All patients had localized disease, 93% of patients had small tumors (<5 cm), and 76% of patients had Intergroup Rhabdomyosarcoma Study (IRS) group I tumors.
Sources: NRSTS 2005 (NCT00334854) · 45
The EpSSG prospective NRSTS 2005 (NCT00334854) trial identified 46 patients with dermatofibrosarcoma protuberans.[45] The median age at diagnosis was 6.9 years (range, 0.4–17.5 years). All patients had localized disease, 93% of patients had small tumors (<5 cm), and 76% of patients had Intergroup Rhabdomyosarcoma Study (IRS) group I tumors.
All patients underwent up-front surgery, and 32 patients required two procedures.
There were 11 patients with IRS group II tumors, 2 of whom went on to have a local recurrence.
After a median follow-up of 49 months (range, 4.2–130.9 months), all patients were alive at the time of this report.
The 5-year EFS rate was 92.6% (95% CI, 78.8%–97.6%), and the OS rate was 100%.
In retrospective reviews, postoperative radiation therapy after incomplete excision may have decreased the likelihood of recurrence.[46,47] Metastatic disease is more likely after multiple recurrences, and radiation or other adjuvant therapy should be considered in patients with recurrences that cannot be managed surgically.[40,42]
Targeted therapy (imatinib)
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
When surgical resection cannot be accomplished or the tumor is recurrent, treatment with imatinib (a tyrosine kinase inhibitor) has been effective in adult patients.[48-50]
Evidence (imatinib):
A systematic review of nine studies examined 152 adult patients with histologically proven dermatofibrosarcoma protuberans who were treated with imatinib.[51]
Sources: 51
A systematic review of nine studies examined 152 adult patients with histologically proven dermatofibrosarcoma protuberans who were treated with imatinib.[51]
The study demonstrated a complete response rate of 5.2%, a partial response rate of 55.2%, and a stable disease rate of 27.6%.
There were no differences in the response rates based on imatinib dosing of either 400 mg or 800 mg per day.
Inflammatory Myofibroblastic Tumor and Epithelioid Inflammatory Myofibroblastic Sarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Clinical presentation
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Inflammatory myofibroblastic tumors are rare tumors that affect soft tissues and visceral organs of children and young adults.[55] They rarely metastasize but tend to be locally invasive. Usual anatomical sites of disease include soft tissue, lungs, spleen, colon, and breast.[52] A review of 42 cases of pediatric inflammatory myofibroblastic tumor of the bladder was published in 2015.[56]
Epithelioid inflammatory myofibroblastic sarcoma is an uncommon subtype of inflammatory myofibroblastic tumors that shows a male predominance and can present from infancy through adulthood.[57-59] This subtype shows epithelioid morphology and a perinuclear or nuclear membrane pattern of immunostaining for ALK.[57] The most common site of presentation is the abdomen, although other primary sites have been reported.[57-59]
Genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Roughly one-half of inflammatory myofibroblastic tumors exhibit a clonal variant that activates the ALK gene (encodes a receptor tyrosine kinase) at chromosome 2p23.[60]
Sources: 60
Most cases of epithelioid inflammatory myofibroblastic sarcoma have RANBP2::ALK gene fusions. RRBP1::ALK gene fusions have also been reported.[57-59] Because RANBP2 localizes to the nuclear pore, this likely explains the perinuclear or nuclear membrane pattern of staining noted for ALK in epithelioid inflammatory myofibroblastic sarcoma.
ROS1 and PDGFRB kinase fusions were identified in 8 of 11 patients (73%) who were negative for ALK by immunohistochemistry.[61][Level of evidence C3]
Sources: 61 · Level of evidence C3
Prognosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Inflammatory myofibroblastic tumors recur frequently but are rarely metastatic.[52-54] Studies of children with inflammatory myofibroblastic tumor show 5-year survival rates higher than 80%.[62]
Epithelioid inflammatory myofibroblastic sarcoma is an aggressive tumor that is generally treated with surgery. Before the availability of ALK inhibitors, disease progression and high mortality rates were common.[57,58,63] Epithelioid inflammatory myofibroblastic sarcoma generally responds to ALK inhibitors but progression on therapy has been observed, which is consistent with the aggressive clinical behavior of the tumor.[59]
Treatment of inflammatory myofibroblastic tumor
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for inflammatory myofibroblastic tumor include the following:
Surgery and chemotherapy.
Sources: Surgery and chemotherapy
Steroid therapy or NSAID therapy.
Sources: Steroid therapy or NSAID therapy
Targeted therapy (ALK inhibitors).
Sources: Targeted therapy (ALK inhibitors)
Surgery and chemotherapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Complete surgical removal, when feasible, is the mainstay of therapy.[64]
Sources: 64
Evidence (surgery with or without chemotherapy):
In a series of nine patients, the following was observed:[65][Level of evidence C1]
Sources: 65 · Level of evidence C1
In a series of nine patients, the following was observed:[65][Level of evidence C1]
Four patients achieved continuous remission after complete resection.
Three patients with residual disease experienced disease recurrence but later achieved continuous remission.
One patient with metastatic disease responded to multiagent chemotherapy.
In another study of 31 patients who underwent complete surgical resection, 4 patients had local disease recurrences.[62]
Sources: 62
In another study of 31 patients who underwent complete surgical resection, 4 patients had local disease recurrences.[62]
Of the 4 patients with local recurrences, all patients were alive after surgical re-resection (3 patients) or adjuvant chemotherapy and resection (1 patient).
A review of German studies identified 37 patients younger than 21 years with inflammatory myofibroblastic tumors.[66][Level of evidence C1]
Sources: 66 · Level of evidence C1
A review of German studies identified 37 patients younger than 21 years with inflammatory myofibroblastic tumors.[66][Level of evidence C1]
Of 20 patients, 17 had complete resections with no recurrences. Surgical resections can be limited to those procedures that preserve form and function.
All other patients were treated with a combination of surgery and various chemotherapy regimens.
The overall 5-year EFS rate was 75%, and the OS rate was 91%.
A series of 32 patients aged 18 years and younger found that complete excision was the mainstay of therapy, although some patients were treated with steroids or cytotoxic chemotherapy.[67][Level of evidence C1]
Sources: 67 · Level of evidence C1
A series of 32 patients aged 18 years and younger found that complete excision was the mainstay of therapy, although some patients were treated with steroids or cytotoxic chemotherapy.[67][Level of evidence C1]
The OS rate was 94%.
Three patients had relapsed disease, two of whom died of the disease.
When complete excision was performed, with or without other treatments such as steroids, there was a high survival rate for these patients.
The benefit of chemotherapy has been noted in case reports.[68] A prospective registry of children with inflammatory myofibroblastic tumor from the EpSSG (2005–2016) found an EFS rate of 82.9% and an OS rate of 98.1% at 5 years in all patients. The response rate for patients who received systemic therapy (chemotherapy or ALK inhibitor therapy) was 63% when used as front-line therapy and 66% when used as second-line therapy. Eight of ten patients who received vinblastine and low-dose methotrexate and all five patients who received ALK inhibitors (all of whom had ALK-positive tumors) responded to treatment.[62]
A retrospective, international, multicenter study analyzed patients younger than 21 years with ROS1-altered inflammatory myofibroblastic tumors who were enrolled in either the EpSSG NRSTS-2005 study or the Soft Tissue Sarcoma Registry. Primary surgery was recommended if a microscopic radical resection without disfigurement was feasible. Of the 19 patients, 12 received neoadjuvant systemic therapy as first-line treatment (high-dose steroids, n = 2; vinorelbine/vinblastine with methotrexate, n = 6; ROS1 inhibitors, n = 8). With a median follow-up of 2.8 years, seven patients had an event. The 3-year EFS rate was 41% (95% CI, 11%–71%), and the OS rate was 100%. While many patients in this series received crizotinib, the specific ROS1 inhibitor used for each patient was not specified.[69]
Sources: 69
Steroid therapy or NSAID therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Targeted therapy (ALK inhibitors)
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Inflammatory myofibroblastic tumors respond to ALK inhibitor therapy, as follows:
Crizotinib
Evidence (crizotinib):
For pediatric patients with measurable disease, the use of crizotinib achieved partial tumor responses in three of six patients with ALK-translocated inflammatory myofibroblastic tumors.[72]
Sources: 72
A case report of a patient aged 16 years with metastatic/multifocal ALK-positive inflammatory myofibroblastic tumor demonstrated a complete response and a 3-year disease-free interval with crizotinib therapy.[73]
Sources: 73
One study included 14 patients with inflammatory myofibroblastic tumors who were treated with crizotinib.[74][Level of evidence C3]
Sources: 74 · Level of evidence C3
One study included 14 patients with inflammatory myofibroblastic tumors who were treated with crizotinib.[74][Level of evidence C3]
Five patients had complete responses, seven had partial responses, and the remaining two had stable disease.
No patient had relapsed disease at the time the article was published.
Two adult patients with ALK-rearranged inflammatory myofibroblastic tumor achieved partial responses with crizotinib.[75][Level of evidence C3]
Sources: 75 · Level of evidence C3
An extensive review confirmed the effectiveness of crizotinib in children with inflammatory myofibroblastic tumors in various locations.[76]
Sources: 76
The FDA approved crizotinib for patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory ALK-positive myofibroblastic tumors.
Ceritinib
Evidence (ceritinib):
Two pediatric patients enrolled in a clinical trial responded to treatment with ceritinib.[77]
Sources: 77
Two pediatric patients enrolled in a clinical trial responded to treatment with ceritinib.[77]
One patient had a complete response that was durable for multiple years on continuing therapy.
The other patient had a partial response when the drug was discontinued for severe liver and renal toxicity.
In a multicenter phase I study of ceritinib, 7 of 10 patients with inflammatory myofibroblastic tumor had objective responses to ceritinib.[78]
Sources: 78
In a phase I trial of ceritinib for adult patients who were previously treated with ALK inhibitors, one patient with inflammatory myofibroblastic tumor had a partial response.[79]
Sources: 79
Alectinib
A case report described the successful treatment of a patient with an inflammatory myofibroblastic tumor and a FN1::ALK gene fusion using alectinib, a second-generation ALK inhibitor.[80]
Sources: 80
For information about the treatment of this tumor in the lungs, see Childhood Pulmonary Inflammatory Myofibroblastic Tumors Treatment.
Sources: Childhood Pulmonary Inflammatory Myofibroblastic Tumors Treatment
Infantile Fibrosarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
There are two distinct types of fibrosarcoma in children and adolescents, as follows:
Infantile fibrosarcoma is a malignant fibroblastic tumor usually characterized by ETV6::NTRK3 gene fusions.
Adult-type fibrosarcoma is composed of monomorphic fibroblastic tumor cells. Some of the genomic features of adult-type fibrosarcoma have been recently described.[81]
Sources: 81
These are two distinct pathological diagnoses and require different treatments.
Clinical presentation
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Infantile fibrosarcoma usually occurs in children younger than 1 year. This tumor usually presents with a rapidly growing mass, often noted at birth or even seen in the prenatal ultrasound. The tumors are frequently quite large at the time of presentation.[82] Hypercalcemia secondary to elevated levels of parathyroid hormone–related protein has been reported as a presenting feature of this disease in newborns.[83]
These tumors have a low incidence of metastases at diagnosis.
Genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
The tumor usually has a characteristic cytogenetic translocation t(12;15)(p13;q25) to create the ETV6::NTRK3 fusion gene. Infantile fibrosarcoma shares this translocation and a virtually identical histological appearance with mesoblastic nephroma.
Infantile fibrosarcoma occasionally occurs in children up to age 4 years. A tumor with similar morphology has been identified in older children. In these older children, the tumors do not have the ETV6::NTRK3 fusion that is characteristic of the tumors in younger patients.[84] BRAF intragenic deletions have been described in cases of infantile fibrosarcoma. Some of these tumors also contained NTRK3 fusions.[85] One study described four young children (aged 2–10 years) with tumors that were histologically classified as infantile fibrosarcoma and had ALK rearrangements.[86]
The Associazione Italiana Ematologia Oncologia Pediatrica analyzed a cohort of 44 pediatric patients with tumors classified as infantile fibrosarcomas/congenital mesoblastic nephromas. Eight infantile fibrosarcoma–like mesenchymal tumors found to be negative for the ETV6::NTRK3 fusion gene were analyzed by RNA sequencing to identify novel driver events. They identified three fusion genes involving RAF1: GOLGA4::RAF1, LRRFIP2::RAF1, and CLIP1::RAF1. The three fusion proteins retained the entire catalytic domain of the RAF1 kinase.[87]
Sources: 87
Treatment of infantile fibrosarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for infantile fibrosarcoma include the following:
Surgery, observation, and/or chemotherapy.
Targeted therapy.
Sources: Targeted therapy
Surgery, observation, and/or chemotherapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Complete resection is curative in most patients with infantile fibrosarcoma. However, the large size of the lesion frequently makes resection without major functional consequences impossible. For instance, tumors of the extremities often require amputation for complete excision.
The European pediatric group has reported that observation may also be an option in patients with microscopic residual disease after surgery.[88] Twelve patients with microscopic residual disease received no further therapy and two patients experienced disease relapse. One patient obtained a complete remission after chemotherapy. Postoperative chemotherapy was administered to patients with higher group disease and those who progressed. In a subsequent study, only one of seven patients with microscopic residual disease progressed during observation. That patient achieved complete remission with chemotherapy.[89][Level of evidence C1]
Sources: 88 · 89 · Level of evidence C1
Preoperative chemotherapy has made a more conservative surgical approach possible. Agents active in this setting include vincristine, dactinomycin, cyclophosphamide, and ifosfamide.[90,91]; [89,92,93][Level of evidence C1] Three older studies of patients with infantile fibrosarcoma suggested that an alkylator-free regimen was effective and used as the first treatment choice in patients with macroscopic disease.[88,89,94] However, newer results of studies using NTRK inhibitors have suggested that kinase inhibitors are an appropriate initial therapy.
Sources: 90 · 91 · 89 · 92 · 93 · Level of evidence C1 · 88 · 89 · 94
Targeted therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Larotrectinib
Larotrectinib is an oral ATP-competitive inhibitor of TRK A, B, and C.
Evidence (larotrectinib):
A phase I/II trial of larotrectinib was completed in patients with recurrent infantile fibrosarcoma who harbored an NTRK gene fusion.[95]
Sources: 95
A phase I/II trial of larotrectinib was completed in patients with recurrent infantile fibrosarcoma who harbored an NTRK gene fusion.[95]
Durable objective responses were seen in all eight patients, and responses occurred at a median of 1.7 months.
Most toxicities were grades 1 and 2, which included transaminitis, leukopenia, neutropenia, and vomiting. There were no grade 4 or grade 5 events attributed to larotrectinib.
In another study, three of five patients who achieved a partial response after neoadjuvant larotrectinib underwent a complete surgical resection with negative margins.[96,97]; [98][Level of evidence C2]
Sources: 96 · 97 · 98 · Level of evidence C2
In another study, three of five patients who achieved a partial response after neoadjuvant larotrectinib underwent a complete surgical resection with negative margins.[96,97]; [98][Level of evidence C2]
These three patients achieved an excellent pathological response (>98% treatment effect) and remained disease free 7 to 15 months after surgery.
In a follow-up report, 159 patients with TRK fusion–positive tumors were enrolled in three phase I/II trials. There were 28 patients with infantile fibrosarcoma who were treated with single-agent larotrectinib.[99][Level of evidence C2]
Sources: 99 · Level of evidence C2
In a follow-up report, 159 patients with TRK fusion–positive tumors were enrolled in three phase I/II trials. There were 28 patients with infantile fibrosarcoma who were treated with single-agent larotrectinib.[99][Level of evidence C2]
The response rate was 96%.
The Children’s Oncology Group conducted a phase II histology-agnostic trial of larotrectinib in children with NTRK fusion–positive solid tumors.[100] The study enrolled 33 patients, 18 with infantile fibrosarcoma and 15 with other solid tumors.
Sources: 100
The Children’s Oncology Group conducted a phase II histology-agnostic trial of larotrectinib in children with NTRK fusion–positive solid tumors.[100] The study enrolled 33 patients, 18 with infantile fibrosarcoma and 15 with other solid tumors.
The overall response rate within six cycles was 94% (17 of 18; 95% adjusted CI, 72.7%–98.6%) for children with infantile fibrosarcoma and 60% (9 of 15; 95% CI, 32.3%–83.7%) for children with other solid tumors.
Six percent (2 of 33; 95% CI, 0.7%–22.2%) of patients developed progressive disease while on therapy.
The 2-year EFS and OS rates among these groups were 82.2% (95% CI, 54.3%–93.9%) and 93.8% (95% CI, 63.2%–99.1%) for infantile fibrosarcoma and 80% (95% CI, 50.0%–93.1%) and 93.3% (95% CI, 61.3%–99.0%) for other solid tumors, respectively.
Patients who underwent surgical resection of their tumor had prolonged EFS, with only 1 of these 16 patients experiencing disease progression.
Other TRK inhibitors
LOXO-195: In a clinical trial, 1 of 8 pediatric patients with an ETV6::NTRK3–rearranged infantile fibrosarcoma developed progressive disease after 8 months of larotrectinib therapy and was found to have an acquired G623R resistance variant. The patient was treated with LOXO-195, a selective TRK inhibitor designed to overcome acquired resistance mediated by recurrent kinase domain variants. The patient experienced a transient partial response.[101] LOXO-195 is no longer being developed.
Sources: 101
VEGFR inhibitor
Pazopanib: A patient aged 2 months with infantile fibrosarcoma was initially treated with chemotherapy. At disease progression, a response was seen with pazopanib therapy.[102]
Sources: 102
Treatment options under clinical evaluation
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Fibrosarcoma NOS
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
These tumors lack the translocation seen in infantile fibrosarcomas. They present like most nonrhabdomyosarcomas, and the management approach is similar.
Myxofibrosarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Myxofibrosarcoma is a rare lesion, especially in childhood. It is typically treated with complete surgical resection.
Low-Grade Fibromyxoid Sarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Low-grade fibromyxoid sarcoma is a histologically deceptive soft tissue neoplasm that most commonly affects young and middle-aged adults. It is commonly located deep within the extremities.[103-105]
A Children's Oncology Group (COG) trial (ARST0332 [NCT00346164]) enrolled 11 patients with this tumor type. The median age at diagnosis was 13 years, and males were more commonly affected. The most common tumor sites were the lower and upper extremities (n = 9). None of the patients developed local or distant disease recurrence at a median follow up of 2.7 years.[106]
Sources: ARST0332 [NCT00346164] · 106
Genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Prognosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
In a review of 33 patients (3 were younger than 18 years) with low-grade fibromyxoid sarcoma, 21 patients developed a local recurrence after intervals of up to 15 years (median, 3.5 years). Fifteen patients developed metastases up to 45 years (median, 5 years) from diagnosis, most commonly to the lungs and pleura. This finding emphasizes the need for continued follow-up of these patients.[103] Even after metastases occur, the disease course may be indolent.[109]
In another report, 14 of 73 patients were younger than 18 years. In this series with a relatively short follow-up (median of 24 months), only 8 of 54 patients with adequate follow-up developed local (9%) or distant (6%) disease recurrence. This report suggested that the behavior of this tumor might be significantly better than previously reported.[110] However, because late metastases can occur, careful monitoring of these patients is warranted.
Sources: 110
A study by the Ultra-Rare Sarcoma Working Group examined 32 patients with rare occurrences of distant metastases (20 with metastases at diagnosis, 12 after initial resection). Most metastases occurred in the lungs. Treatments varied, and minimal responses were observed to anthracycline-based and gemcitabine-based regimens with trabectidin. However, there were few patients in each treatment group.[111]
Sources: 111
Treatment of low-grade fibromyxoid sarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for low-grade fibromyxoid sarcoma include the following:
Surgery.
Low-grade fibromyxoid sarcoma is not very chemosensitive, and the limited treatment information suggests that surgery is the treatment of choice.[109]
Sources: 109
Evidence (surgery):
The German Cooperative Weichteilsarkom Studiengruppe (CWS) reported study results for 31 patients younger than 21 years with low-grade fibromyxoid sarcoma.[104][Level of evidence C2]
Sources: 104 · Level of evidence C2
The German Cooperative Weichteilsarkom Studiengruppe (CWS) reported study results for 31 patients younger than 21 years with low-grade fibromyxoid sarcoma.[104][Level of evidence C2]
The 5-year EFS rate was 71% (95% CI, ±18.6%), the 5-year local relapse-free survival rate was 76% (95% CI, ±17.6%), and the 5-year OS rate was 100%.
Among 24 patients who had R0 resections (complete resection with negative microscopic margins), 5 patients (21%) experienced disease relapses (3 local, 1 metastatic, and 1 combined).
Among seven patients who had R1 resections (margins were microscopically positive), three patients (43%) experienced local disease relapses.
There are little data regarding the use of chemotherapy and/or radiation therapy in this disease. One report suggests that trabectedin may be effective in the treatment of low-grade fibromyxoid sarcoma.[112]
Sources: 112
Sclerosing Epithelioid Fibrosarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Genomic characteristics
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Sclerosing epithelioid fibrosarcoma most commonly has the EWSR1::CREB3L1 gene fusion. However, EWSR1 may have other partners, including CREB3L2 and CREB3L3.[115,116] Gene fusions involving FUS (including the FUS::CREB3L2 fusion associated with low-grade fibromyxoid sarcoma) and PAX5 (e.g., PAX5::CREB3L1) are uncommon but can occur.[116,117] For cases of sclerosing epithelioid fibrosarcoma that lack MUC4 expression, EWSR1 gene fusions are generally absent, while a gene fusion involving YAP1 and KMT2A is commonly observed.[113,115,118,119] Sclerosing epithelioid fibrosarcoma has more structural and chromosomal segmental alterations than low-grade fibromyxoid fibrosarcoma.[115]
Sources: 115 · 116 · 116 · 117 · 113 · 115 · 118 · 119 · 115
Treatment of sclerosing epithelioid fibrosarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for sclerosing epithelioid fibrosarcoma include the following:
Surgery.
The tumor responds poorly to chemotherapy.[120] Therefore, it is typically treated with complete surgical excision. Long-term follow-up is recommended because late local recurrences and metastases can occur.
Sources: 120
Treatment of Skeletal Muscle Tumors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Skeletal muscle tumors have several subtypes, including the following:
Rhabdomyosarcoma.
Sources: Rhabdomyosarcoma
Ectomesenchymoma.
Sources: Ectomesenchymoma
Rhabdomyosarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
For more information, see Childhood Rhabdomyosarcoma Treatment.
Sources: Childhood Rhabdomyosarcoma Treatment
Ectomesenchymoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Ectomesenchymoma is a rare skeletal muscle tumor that mainly occurs in children. It is a biphenotypic soft tissue sarcoma with both mesenchymal and ectodermal components.
A single-institution retrospective review identified seven cases of malignant ectomesenchymoma.[1] All seven patients were male, with a mean age of 7.5 months (range, 0.6–17.0 months). Five of the seven patients in this series were healthy and free of disease at the time of reporting.
Sources: 1
Histological features and genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
A retrospective review of six patients with malignant ectomesenchymoma from a single institution identified rhabdomyosarcoma as the mesenchymal element in five of six tumors.[2] Tumors with an alveolar rhabdomyosarcoma morphology exhibited the characteristic translocations, including translocation of the FOXO1 gene fusing with the PAX3 or PAX7 gene. No unifying molecular aberrations were identified.
Sources: 2
A single-institution retrospective review identified seven cases of malignant ectomesenchymoma.[1] Most patients showed elements of embryonal rhabdomyosarcoma. The mixed neuroectodermal elements were scattered ganglion cells, ganglioneuroma, or ganglioneuroblastoma. Six of seven cases had HRAS variants. The trimethylation at lysine 27 of histone H3 (H3K27me3), typically lost in malignant peripheral nerve sheath tumor, was retained in all cases.
Sources: 1
Treatment of ectomesenchymoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for ectomesenchymoma include the following:
Surgery.
Chemotherapy.
Radiation therapy.
The Cooperative Weichteilsarkom Studiengruppe (CWS) reported on six patients (aged 0.2–13.5 years) registered over 14 years.[3][Level of evidence C1] The tumors were located in various sites, including the extremities, abdomen, and orbit. All six patients were treated with surgery and chemotherapy directed at rhabdomyosarcoma. Two patients received radiation therapy. Three patients experienced tumor recurrences with rhabdomyosarcoma features. Although data are scant, it appears that the tumor may respond to chemotherapy.[3]
Sources: 3 · Level of evidence C1 · 3
The European paediatric Soft Tissue Sarcoma Study Group (EpSSG) identified ten patients with ectomesenchymoma in a prospectively recorded database.[4] Of the ten cases, seven had an initial local diagnosis of rhabdomyosarcoma. All patients received chemotherapy according to rhabdomyosarcoma strategy, and four patients received radiation therapy. Overall, six patients were alive in first remission, two in second remission, and one after treatment for a second primary cancer. Only the patient with a metastatic tumor at diagnosis died of their disease.
Sources: 4
Treatment of Smooth Muscle Tumors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Leiomyosarcoma Not Otherwise Specified (NOS)
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Leiomyosarcoma accounts for 2% of soft tissue sarcomas in patients younger than 20 years (see Table 1).
Sources: Table 1
Risk factors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Among 43 children with HIV/AIDS who developed tumors, 8 developed Epstein-Barr virus–associated leiomyosarcoma.[1] Survivors of hereditary retinoblastoma have a statistically significant increased risk of developing leiomyosarcoma, and 78% of these patients were diagnosed 30 or more years after the initial diagnosis of retinoblastoma.[2]
Treatment of leiomyosarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
There are no standard treatment options for leiomyosarcoma in pediatric patients.
Trabectedin, an alkylating drug with multiple mechanisms of action that damage DNA, has been studied in adults with leiomyosarcoma. There are no studies using trabectedin to treat leiomyosarcoma in pediatric patients.
Results from studies in adult patients include the following:
In an open-label study of trabectedin in adult patients with recurrent sarcomas, the best overall response rate (complete remission and partial remission) was seen in patients with leiomyosarcoma (7.5%).[3] The clinical benefit rate (included stable disease) was 54% for patients with leiomyosarcoma.
Sources: 3
In another adult study, patients with recurrent liposarcoma and leiomyosarcoma were randomly assigned to receive treatment with either trabectedin or dacarbazine. Patients treated with trabectedin had a 45% reduction in disease progression.[4]
Sources: 4
The French Sarcoma group conducted a randomized trial for the treatment of adult patients with leiomyosarcoma (age range, 52–69 years).[5] Patients were randomly assigned to receive either single-agent doxorubicin (six cycles) or doxorubicin with trabectedin, with continued maintenance therapy using trabectedin for patients in the doxorubicin/trabectedin group who did not have disease progression. Surgery to resect residual disease was allowed in each group after six cycles of therapy. The median overall survival was longer in the doxorubicin/trabectedin group (33 months; 95% confidence interval [CI], 26–48) than in the doxorubicin group (24 months; 95% CI, 19–31). The adjusted hazard ratio for death was 0.65 (95% CI, 0.44–0.95).
Sources: 5
Treatment of So-Called Fibrohistiocytic Tumors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Plexiform Fibrohistiocytic Tumor
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Plexiform fibrohistiocytic tumor is a rare, low- to intermediate-grade so-called fibrohistiocytic tumor that most commonly affects children and young adults. The median age at presentation ranges from 8 to 14.5 years. However, the tumor has been described in patients as young as 3 months.[1,2]
Clinical presentation
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
The tumor commonly arises as a painless mass in the skin or subcutaneous tissue and most often involves the upper extremities, including the fingers, hand, and wrist.[3-5] Plexiform fibrohistiocytic tumor is an intermediate-grade tumor that rarely metastasizes. However, there are rare reports of the tumor spreading to regional lymph nodes or the lungs.[1,5,6]
Genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
No consistent chromosomal anomalies have been detected, but a t(4;15)(q21;q15) translocation has been reported.[7]
Sources: 7
Treatment of plexiform fibrohistiocytic tumor
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for plexiform fibrohistiocytic tumor include the following:
Surgery.
Surgery is the treatment of choice, but local recurrence has been reported in 12% to 50% of cases.[8]
Sources: 8
Treatment of Peripheral Nerve Sheath Tumors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Peripheral nerve sheath tumors have several subtypes, including the following:
Malignant peripheral nerve sheath tumor (MPNST) not otherwise specified (NOS).
Sources: Malignant peripheral nerve sheath tumor (MPNST) not otherwise specified (NOS)
Malignant triton tumor.
Sources: Malignant triton tumor
Malignant Peripheral Nerve Sheath Tumor (MPNST) NOS
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
MPNSTs account for 5% of soft tissue sarcomas in patients younger than 20 years (see Table 1).
Sources: Table 1
Risk factors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
MPNST can arise sporadically and in children with neurofibromatosis type 1 (NF1).[1] Among patients with NF1, a family history of MPNST is associated with an increased risk of developing early-onset MPNST.[2]
A rare case of a child with documented neurofibromatosis type 2 (NF2) and a benign neurofibroma had five recurrences of disease. During this time, the lesions progressively lost markers (such as S-100) and acquired clear-cut signs of malignant transformation to MPNST, documented by multiple markers, including the first example of NOTCH2 in this disease.[3]
Sources: 3
Histological features, diagnostic evaluation, and genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
The molecular pathogenesis of adult MPNSTs demonstrates inactivating variants in at least three pathways, including NF1, CDKN2A, CDKN2B, and PRC2 complex core components. Similar alterations have been reported in pediatric tumors.[4]
Sources: 4
Inactivating variants of SUZ12 have been described in these tumors and are absent in neurofibromas.[5]
Sources: 5
A DNA methylation array for methylome-based and profile-based chromosomal characterization was performed on 171 peripheral nerve sheath tumors.[6] Atypical neurofibromas and low-grade MPNSTs were indistinguishable, with a common methylation profile and loss of CDKN2A. Epigenomic analysis identified two groups of conventional high-grade MPNSTs sharing a frequent loss of neurofibromin. The larger group showed an additional loss of trimethylation of H3K27me3. The smaller group of patients with predominantly spinal primary sites showed retention of H3K27me3.
Sources: 6
Genomic profiling was performed on 201 MPNSTs.[7] Thirteen of 201 tumors demonstrated BRAF alterations.
Sources: 7
The Memorial Sloan Kettering Cancer Center studied archival and consultation material from 64 pediatric and young adult patients (aged 20 years or younger).[4] Fifty-eight percent of patients had a clinical history of NF1. All but one patient had high-grade MPNSTs. Overall, 89% of patients were classified as having high-grade MPNSTs, and 94% of patients had conventional histological features. There were 16 high-grade tumors available for molecular characterization using the MSK-IMPACT assay. These pediatric and adolescent tumors had genomic driver events that were similar to those in adult tumors. The study found genomic perturbations in PRC2 components (SUZ12 or EED; 9 cases), NF1 variants (8 cases), and CDKN2A and CDKN2B deletions (8 cases). Loss of HDK27me3 expression was noted in 82% of conventional high-grade MPNSTs. This finding is a potentially powerful immunohistochemical diagnostic marker for pediatric MPNSTs.
Sources: 4
Prognostic factors and prognosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Smaller tumor size. In a multivariate analysis, only tumor size and nuclear TP53 expression were found to be independent predictors of disease-specific survival.[9]
Sources: 9
Male sex.[11]
Sources: 11
Non-Hispanic White race.[11]
Sources: 11
Lower stage.
Lower histological grade.
Extremity as the primary site.
Factors associated with an unfavorable prognosis include the following:[12]
Sources: 12
High grade.
Deep tumor location.
Locally advanced stage at diagnosis.
Presence of metastasis at diagnosis. A retrospective review of 140 patients with MPNST from the MD Anderson Cancer Center included children and adolescents. The disease-specific survival at 10 years was 32%. In this series, presence of metastatic disease was associated with a much worse prognosis.[9]
Sources: 9
Macroscopically incomplete resection (R2).
Inactivation of TP53, either by variant or amplification of MDM2.[13]
Sources: 13
High expression of TP53 and cyclin D1. These markers were identified as adverse prognostic factors using immunohistochemical staining of diagnostic biopsy tissue.[14][Level of evidence C2]
Sources: 14 · Level of evidence C2
Presence of NF1 appears to be associated with an unfavorable prognosis, but the data are mixed.[4,15]
For patients with localized disease in the MD Anderson Cancer Center study, there was no significant difference in outcome between patients with and without NF1.[9] In other studies, it was not clear whether the absence of NF1 was a favorable prognostic factor as it has been associated with both favorable [8] and unfavorable outcomes.[1,8,10]
In the French Sarcoma Group study, NF1 was associated with other adverse prognostic features, but was not an independent predictor of poor outcome.[12] A retrospective analysis of cancer registry data from the Netherlands identified 784 patients with MPNST; 70 of the patients were aged 18 years or younger.[16][Level of evidence C1] In children with NF1, large tumor size was more common (>5 cm, 92.3% vs. 59.1%). Overall, the estimated 5-year survival rate was 52.4% (standard error [SE], 10.1%) for patients with localized MPNST and NF1, compared with 75.8% (SE, 7.1%) for patients without NF1.
Sources: 12 · 16 · Level of evidence C1
The Cooperative Weichteilsarkom Studiengruppe (CWS) reported a retrospective review of patients with MPNST who were treated on five consecutive CWS trials.[17] A total of 159 patients were analyzed. NF1 was reported in 38 patients (24%). Nodal involvement was documented in 15 patients (9%) at diagnosis, and distant metastases was noted in 15 patients (9%) at diagnosis. Overall, the event-free survival (EFS) rate was 40.5% at 5 years and 36.3% at 10 years. The overall survival (OS) rate was 54.6% at 5 years and 47.1% at 10 years. Older age, positive NF1 status, primary tumor site other than extremity, larger tumor size, higher Intergroup Rhabdomyosarcoma Study (IRS) group, presence of metastatic disease, and failure to achieve first complete remission were identified as adverse prognostic factors for EFS and/or OS in the univariate analysis.
Sources: 17
Treatment of MPNST
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for MPNST include the following:
Surgery preceded or followed by radiation therapy.[18,19]
Sources: Surgery preceded or followed by radiation therapy · 18 · 19
Chemotherapy, for unresectable tumors.
Sources: Chemotherapy
Surgery preceded or followed by radiation therapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Complete surgical removal of the tumor, whenever possible, is the mainstay of treatment.
The role of radiation therapy is difficult to assess, but durable local control of known postoperative microscopic residual tumor is not ensured after radiation therapy.
Chemotherapy
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Chemotherapy has achieved objective responses in childhood MPNST.
Evidence (chemotherapy):
A large retrospective analysis of the German and Italian experience with this tumor reported the following results:[1]
Sources: 1
A large retrospective analysis of the German and Italian experience with this tumor reported the following results:[1]
Sixty-five percent of measurable tumors had objective responses to ifosfamide-containing chemotherapy regimens.
The analysis did not conclusively demonstrate improved survival with chemotherapy.
This retrospective analysis also noted a trend toward improved outcome with postoperative radiation therapy.
A series of 37 young patients with MPNST and NF1 showed that most patients had large invasive tumors that were poorly responsive to chemotherapy.[20]
Sources: 20
A series of 37 young patients with MPNST and NF1 showed that most patients had large invasive tumors that were poorly responsive to chemotherapy.[20]
The progression-free survival (PFS) rate was 19%, and the 5-year OS rate was 28%.
The European paediatric Soft Tissue Sarcoma Study Group (EpSSG) performed a prospective study in patients aged 21 years and younger with MPNST.[21] Surgical resection of primary tumors was classified as R0 if the resection was complete with negative microscopic margins, R1 if the margins were microscopically positive, and R2 if the resection left macroscopic residual tumor. Patients were nonrandomly assigned to one of the following four treatment groups:For patients who received chemotherapy, treatment consisted of four courses of ifosfamide/doxorubicin and two courses of ifosfamide concomitant with radiation therapy (50.4–54 Gy).
Sources: 21
The European paediatric Soft Tissue Sarcoma Study Group (EpSSG) performed a prospective study in patients aged 21 years and younger with MPNST.[21] Surgical resection of primary tumors was classified as R0 if the resection was complete with negative microscopic margins, R1 if the margins were microscopically positive, and R2 if the resection left macroscopic residual tumor. Patients were nonrandomly assigned to one of the following four treatment groups:For patients who received chemotherapy, treatment consisted of four courses of ifosfamide/doxorubicin and two courses of ifosfamide concomitant with radiation therapy (50.4–54 Gy).
Cohort 1: Patients with completely resected tumors (R0) who received surgery only (n = 13); the 5-year EFS rate was 92%.
Cohort 2: Patients with incompletely resected tumors (R1/R2) who received adjuvant radiation therapy (n = 4); the 5-year EFS rate was 33%.
Cohort 3: Patients with incompletely resected tumors (R1/R2) who received adjuvant chemotherapy (n = 7); the 5-year EFS rate was 29%.
Cohort 4: Patients who received either chemotherapy before surgical resection and/or who had nodal involvement (n = 27); the 5-year EFS rate was 52%.
The response rate to chemotherapy (partial response + complete response) in patients with measurable disease was 46%.
The presence of NF1 (51% of patients) was an independent poor prognostic factor for OS and EFS.
In a study of pediatric and adult patients with either sporadic (n = 14) or chemotherapy-naïve, NF1-associated (n = 34) MPNST, patients were treated with two cycles of ifosfamide and doxorubicin and two cycles of ifosfamide and etoposide.[22]
Sources: 22
In a study of pediatric and adult patients with either sporadic (n = 14) or chemotherapy-naïve, NF1-associated (n = 34) MPNST, patients were treated with two cycles of ifosfamide and doxorubicin and two cycles of ifosfamide and etoposide.[22]
Response rates were lower in patients with NF1-associated tumors than in patients with sporadic tumors (17.9% vs. 44.4%). However, the premature closure of the study did not allow sufficient power to detect meaningful differences in objective responses between the two groups.
The rates of stable disease were similar between the two groups.
Recurrent MPNST
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Of 120 patients enrolled in Italian pediatric protocols from 1979 to 2004, an analysis identified 73 patients younger than 21 years with relapsed MPNST. Treatment options included surgery, radiation therapy, and chemotherapy.[23]
Sources: 23
The time to relapse from initial diagnosis ranged from 1 month to 204 months, with a median time to relapse of 7 months.
Median OS from first relapse was 11 months, with an OS rate of 39% at 1 year and 16% at 5 years.
The factors associated with a higher probability of survival after relapse were lower tumor invasiveness at initial presentation, longer time to relapse, and complete surgical resection of the tumor at relapse.
A retrospective study evaluated nine patients with unresectable or metastatic MPNST (seven patients were previously treated) who were treated with selinexor with or without doxorubicin. Three patients experienced a partial response that lasted for 3 months to longer than 8 months, and four patients had stable disease.[24]
Sources: 24
Treatment options under clinical evaluation
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
NCT04465643 (Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor): The purpose of the study is to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab before standard therapy (surgery, chemotherapy, or radiation therapy) in patients with NF1 and newly diagnosed premalignant and malignant peripheral nerve sheath tumors for whom surgery for resection of tumor is indicated.
Sources: NCT04465643
Malignant Triton Tumor
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Malignant triton tumors are now classified as a variant of MPNSTs. They occur most often in patients with NF1 and consist of neurogenic and rhabdomyoblastic components.[25] Most malignant triton tumors are reported in adults, although they may also arise in children and adolescents.[26]
Distinguishing between malignant triton tumors and NF1-altered rhabdomyosarcomas can be difficult. The genomic characteristics of malignant triton tumors can aid in differentiating between the two tumors. CDKN2A deep deletions and loss-of-function alterations in genes of the PRC2 complex (e.g., SUZ12 and EED1) are commonly observed in malignant triton tumors, while they are uncommon in NF1-altered rhabdomyosarcomas. The loss of PRC2 function leads to loss of H3K27me3 expression, a finding that is common in malignant triton tumors. H3K27me3 expression is generally maintained in rhabdomyosarcomas.[26-28]
Treatment of Pericytic (Perivascular) Tumors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Pericytic (perivascular) tumors have several subtypes, including the following:
Myopericytoma.
Sources: Myopericytoma
Infantile myofibromatosis.
Sources: Infantile myofibromatosis
Myopericytoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Histology
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Histologically, hemangiopericytomas are composed of packed round or fusiform cells that are arranged around a complex vasculature, forming many branch-like structures. Hyalinization is often present. Infantile hemangiopericytomas have similar histology but many are multilobular with vasculature outside the tumor mass.[4]
Sources: 4
Treatment and outcome of infantile hemangiopericytomas
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for infantile hemangiopericytomas include the following:
Chemotherapy.
Evidence (chemotherapy):
In a series of 17 children, the differences in metastatic potential and response to treatment were clearly demonstrated for adult and infantile hemangiopericytomas. Eleven children were older than 1 year. Several of these patients had disease in the lymph nodes or lungs.[5]
Sources: 5
In a series of 17 children, the differences in metastatic potential and response to treatment were clearly demonstrated for adult and infantile hemangiopericytomas. Eleven children were older than 1 year. Several of these patients had disease in the lymph nodes or lungs.[5]
Three patients with stage I disease survived, although one patient had recurrence in the lungs.
Eight patients had stage II or stage III disease. Two of these patients survived and six patients had disease progression and died.
Six patients had infantile hemangiopericytoma, five of which were greater than stage I. All six patients survived, and three patients had good responses to vincristine, actinomycin, and cyclophosphamide.
Several studies have reported on soft tissue sarcomas in children that were more akin to infantile myofibromatosis or hemangiopericytoma.[6,7] Rather than the ETV6::NTRK3 fusion protein seen in congenital infantile fibrosarcoma, a LMNA::NTRK1 fusion protein was identified.[8] One patient carrying this fusion responded to crizotinib. For more information about infantile myofibromatosis, see the Infantile Myofibromatosis section.
Sources: 6 · 7 · 8 · Infantile Myofibromatosis
Infantile Myofibromatosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Infantile myofibromatosis is a fibrous tumor of infancy and childhood that most commonly presents in the first 2 years of life.[9]
Sources: 9
Genomic alterations and genetic testing
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Somatic gain-of-function PDGFRB variants have been identified in sporadic cases of infantile myofibromatosis, including activating single nucleotide variants and in-frame indels and duplications.[14,15] PDGFRB variants are observed in most cases with multicentric nodules, but are less common in cases with solitary myofibroma.[15,16] Some PDGFRB variants that cause infantile myofibromatosis are sensitive to tyrosine kinase inhibitors like imatinib.[15,16]
An inherited autosomal dominant form of infantile myofibromatosis has been described. It is associated with germline pathogenic variants of the PDGFRB gene, with the R561C variant being most commonly observed.[17-19] The R561C variant is a relatively weak activator of PDGFRB, which may explain the presence of additional PDGFRB variants with stronger activity in some familial infantile myofibromatosis cases.[16,17]
The European Society for Paediatric Oncology Host Genome Working Group developed counseling and germline testing guidelines for these groups of children. This group recommends germline analysis for children with infantile myofibromatosis who have at least one of the following criteria:[20]
Sources: 20
Multicentric disease.
First- or second-degree relatives with infantile myofibromatosis or soft tissue nodules during childhood.
A known PDGFRB germline pathogenic variant in the family.
Suspected germline mosaic PDGFRB pathogenic variants.
Treatment and outcome of infantile myofibromatosis
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Patients with these tumors usually have an excellent prognosis and the tumors can regress spontaneously. However, about one-third of cases with multicentric involvement will also have visceral involvement, and the prognosis for these patients is poor.[12,13,21]
Treatment options for infantile myofibromatosis include the following:
Observation.
Chemotherapy.
Tyrosine kinase inhibitors effective against PDGFRB.
Ninety-five patients were prospectively enrolled in five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry trial between 1981 and 2016.[22] Localized disease was diagnosed in 71 patients. Forty-two (59%) of these patients were infants younger than 12 months. The mainstay of treatment (applied to 55 children) was watch and wait after initial biopsy or resection. Systemic therapy was only recommended in cases of life-threatening progressive disease or in cases of compression of vital structures or organ dysfunction in the setting of progressive disease. Based on these criteria, chemotherapy was administered to 16 of 71 patients as an individual decision at the treating center: 8 patients received methotrexate/vinblastine, 5 patients received vincristine/dactinomycin/cyclophosphamide (VAC), and 3 patients received other therapies.
Sources: 22
Of the patients who received chemotherapy, nine could be assessed for response. Two patients experienced a complete remission (CR) or partial remission (PR) (objective response rate, 22%).
Overall, 77 patients were alive in CR, and 10 patients were alive in PR. Three patients died of progressive disease.
The 5-year event-free survival (EFS) rate was 73% for patients with localized disease and 51% for patients with multifocal disease.
The 5-year overall survival (OS) rate was 95% for patients with localized or multifocal disease.
The use of combination chemotherapy with vincristine/dactinomycin and vinblastine/methotrexate have proven effective in cases of multicentric disease with visceral involvement and in cases in which the disease has progressed and has threatened the life of the patient (e.g., upper airway obstruction).[12,13,23]
Treatment of Tumors of Uncertain Differentiation
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Tumors of uncertain differentiation have many subtypes, including the following:
Myxoma not otherwise specified (NOS) (benign).
Synovial sarcoma NOS (poorly differentiated, spindle cell, and biphasic varieties).
Sources: Synovial sarcoma NOS (poorly differentiated, spindle cell, and biphasic varieties)
Epithelioid sarcoma.
Sources: Epithelioid sarcoma
Alveolar soft part sarcoma.
Sources: Alveolar soft part sarcoma
Clear cell sarcoma NOS.
Sources: Clear cell sarcoma NOS
Extraskeletal myxoid chondrosarcoma.
Sources: Extraskeletal myxoid chondrosarcoma
Desmoplastic small round cell tumor.
Sources: Desmoplastic small round cell tumor
Rhabdoid tumor NOS (extrarenal).
Sources: Rhabdoid tumor NOS (extrarenal)
Perivascular epithelioid tumor (PEComa), malignant.
Undifferentiated sarcoma.
Sources: Undifferentiated sarcoma
Pleomorphic sarcoma, undifferentiated.
Intracranial mesenchymal tumor.
Sources: Intracranial mesenchymal tumor
Round cell sarcoma, undifferentiated.
Sources: Round cell sarcoma, undifferentiated
Myxoma NOS
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Carney complex
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Carney complex is an autosomal dominant syndrome caused by variants in the PRKAR1A gene, located on chromosome 17.[1] The syndrome is characterized by cardiac and cutaneous myxomas, pale brown to brown lentigines, blue nevi, primary pigmented nodular adrenocortical disease causing Cushing syndrome, and a variety of endocrine and nonendocrine tumors, including pituitary adenomas, thyroid tumors, and large cell calcifying Sertoli cell tumor of the testis.[1-3] There are published surveillance guidelines for patients with Carney complex that include cardiac, testicular, and thyroid ultrasonography.
Sources: 1 · 1 · 3 · guidelines
For patients with the Carney complex, prognosis depends on the frequency of recurrences of cardiac and skin myxomas and other tumors.
For more information about the treatment of conditions related to Carney complex, see the following summaries:
Childhood Cardiac Tumors Treatment.
Sources: Childhood Cardiac Tumors Treatment
Childhood Testicular Cancer Treatment.
Childhood Thyroid Cancer Treatment.
Sources: Childhood Thyroid Cancer Treatment
Synovial Sarcoma NOS (Poorly Differentiated, Spindle Cell, and Biphasic Varieties)
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Synovial sarcoma accounts for 9% of soft tissue sarcomas in patients younger than 20 years (see Table 1).
Sources: Table 1
Synovial sarcoma is one of the most common nonrhabdomyosarcomatous soft tissue sarcoma (NRSTS) in children and adolescents. In a review of the Surveillance, Epidemiology, and End Results (SEER) Program database from 1973 to 2005, 1,268 patients with synovial sarcoma were identified. Approximately 17% of these patients were children and adolescents, and the median age at diagnosis was 34 years.[4] In addition, in the Children's Oncology Group (COG) ARST0332 (NCT00346164) and European paediatric Soft Tissue Sarcoma Study Group (EpSSG) 2005 protocols, synovial sarcoma was the single most common histological subtype.[5]
Sources: 4 · ARST0332 (NCT00346164) · 5
Clinical presentation
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
The most common primary tumor location is the extremities, followed by trunk and head and neck.[4] Rarely, a synovial sarcoma may arise in the heart or pericardium or appear with a pleuropulmonary presentation.[6-9]
The most common site of metastasis is the lung.[10,11] The risk of metastases is highly influenced by tumor size. Patients with tumors that are larger than 5 cm have an estimated 32-fold higher risk of developing metastases compared with patients who have tumors smaller than 5 cm.
The Cooperative Weichteilsarkom Studiengruppe (CWS) reported on 432 patients younger than 21 years diagnosed with synovial sarcoma between 1981 and 2018.[12] The study compared three age groups of patients: children (aged 0–12 years; n = 176), adolescents (aged 13–16 years; n = 178), and young adults (aged 17–21 years; n = 78).
Sources: 12
The proportion of invasive tumors was significantly higher in older patients (children, 33%; adolescents, 39%; and young adults, 54%; P = .009).
The proportion of tumors larger than 10 cm (children, 13%; adolescents, 21%; and young adults, 31%; P = .006) and the presence of metastasis at first diagnosis were also higher in older patients (children, 6%; adolescents, 10%; and young adults, 21%; P = .001).
Histological features, diagnostic evaluation, and genomic alterations
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Synovial sarcoma can be subclassified as the following types:
Synovial sarcoma, spindle cell.
Synovial sarcoma, biphasic.
Synovial sarcoma, poorly differentiated.
The diagnosis of synovial sarcoma is made by immunohistochemical analysis, ultrastructural findings, and demonstration of the specific chromosomal translocation t(x;18)(p11.2;q11.2). This abnormality is specific for synovial sarcoma and is found in all morphological subtypes. Synovial sarcoma results in rearrangement of the SS18 gene on chromosome 18 with one of the subtypes (1, 2, or 4) of the SSX gene on chromosome X.[13,14] It is thought that the SS18::SSX fusion transcript promotes epigenetic silencing of key tumor suppressor genes.[15]
In one report, reduced SMARCB1 nuclear reactivity on immunohistochemical staining was seen in 49 cases of synovial sarcoma, suggesting that this pattern may help distinguish synovial sarcoma from other histologies.[16]
Sources: 16
Prognostic factors
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Favorable prognostic factors
Patients younger than 10 years have more favorable outcomes and clinical features than older patients.
Extremity primary tumors.
Smaller tumors.
Localized disease.
Response to chemotherapy was correlated with improved survival in one meta-analysis.
Unfavorable prognostic factors
The following studies have reported multiple factors associated with unfavorable outcomes:
In a retrospective analysis of synovial sarcoma in children and adolescents who were treated in Germany and Italy, tumor size (>5 cm or ≤5 cm in greatest dimension) was an important predictor of event-free survival (EFS).[20] In this analysis, local invasiveness conferred an inferior probability of EFS, but surgical margins were not associated with clinical outcome.
Sources: 20
In a single-institution retrospective analysis of 111 patients with synovial sarcoma who were younger than 22 years at diagnosis, larger tumor size, greater depth in tissue, greater local invasiveness, and more proximal tumor location were associated with poorer overall survival (OS).[21][Level of evidence C1]
Sources: 21 · Level of evidence C1
A multicenter analysis included 219 children from various treating centers, including Germany, St. Jude Children's Research Hospital (SJCRH), Instituto Tumori, and MD Anderson Cancer Center. The study reported an estimated 5-year OS rate of 80% and an EFS rate of 72%.[19] In this analysis, an interaction between tumor size and invasiveness was observed. In multivariate analysis, patients with large or invasive tumors or with Intergroup Rhabdomyosarcoma Study (IRS) group III disease (localized, incompletely resected or with biopsy only) and group IV disease (metastases at diagnosis) had decreased OS. Treatment with radiation therapy was related to improved OS (hazard ratio [HR], 0.4; 95% confidence interval [CI], 0.2–0.7). In patients with IRS group III disease, objective response to chemotherapy (18 of 30 [60%]) correlated with improved survival.
Sources: 19
Expression and genomic index prognostic signatures have been studied in synovial sarcoma. Complex genomic profiles, with greater rearrangement of the genome, are more common in adults than in younger patients with synovial sarcoma and are associated with a higher risk of metastasis.[22]
Sources: 22
A review of 84 patients with localized synovial sarcoma who had information on fusion status (SS18::SSX) and histological grading found no difference in OS according to these criteria. However, for tumor size at diagnosis, the study showed that patients with tumors between 5 cm and 10 cm had a worse prognosis than those with smaller tumors (P = .02). Patients with tumors larger than 10 cm had an even worse OS (P = .0003).[23][Level of evidence C1]
Sources: 23 · Level of evidence C1
The German CWS group reviewed 27 evaluable patients younger than 21 years with pulmonary metastases among 296 patients with synovial sarcoma. All patients had metastasis to the lungs. The 5-year EFS rate was 26%, and the OS rate was 30%. The most important prognostic factor at presentation was that the metastases were limited to one lesion in one lung or one lesion in both lungs (a group they termed oligometastatic). Treatment elements associated with superior survival were adequate local therapy of the primary tumor and, if feasible, for the metastases. The use of whole-lung irradiation did not correlate with better outcomes.[24][Level of evidence C1]
Sources: 24 · Level of evidence C1
The EpSSG designed a genomic index for synovial sarcoma.[25][Level of evidence C2] Genomic index was defined as A2/C, where A is the total number of alterations (segmental gains and losses) and C is the number of involved chromosomes on array comparative genomic hybridization results. In a multivariate analysis of 61 pediatric, adolescent, and young adult patients (aged <25 years), high genomic index was an independent predictor of decreased EFS and OS.
Sources: 25 · Level of evidence C2
Treatment of synovial sarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Treatment options for synovial sarcoma include the following:
Surgery alone.
Sources: Surgery alone
Surgery and chemotherapy, with or without radiation therapy.[29,30]
Sources: Surgery and chemotherapy, with or without radiation therapy · 29 · 30
Surgery alone
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025. Captured 2026-09-09.
Evidence (surgery alone):
The COG and the EpSSG reported a combined analysis of 60 patients younger than 21 years with localized synovial sarcoma prospectively assigned to surgery without adjuvant radiation therapy or chemotherapy.[31] Enrollment was limited to patients with initial complete resection with histologically free margins, with a grade 2 tumor of any size or a grade 3 tumor 5 cm or smaller.
Sources: 31
The COG and the EpSSG reported a combined analysis of 60 patients younger than 21 years with localized synovial sarcoma prospectively assigned to surgery without adjuvant radiation therapy or chemotherapy.[31] Enrollment was limited to patients with initial complete resection with histologically free margins, with a grade 2 tumor of any size or a grade 3 tumor 5 cm or smaller.
The 3-year EFS rate was 90% (median follow-up, 5.2 years; range, 1.9–9.1 years).
All eight events were local tumor recurrence; no metastatic recurrences were seen.
All patients with recurrent disease were effectively treated with second-line therapy, resulting in an OS rate of 100%.
Therefore, the authors concluded that a surgery-only approach was optimal for patients who achieved an R0 resection (complete resection with negative microscopic margins) and had tumors smaller than 5 cm, regardless of grade.
Triangle